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1INTRODUCTION
Effective pain control is essential for care of surgical patients.
Adequate post-operative pain relief must be an integral part of
administration of anaesthesia. Inadequate post-operative pain relief may
result in clinical and psychological changes that may increase the
morbidity  and  mortality  as  well  as  the  cost  of  treatment  as  a  whole,  in
addition to decreasing the quality of life post-operatively.
Intrathecal local anaesthetic agent was first used by Bier. After
several years of development, the technique and concept of spinal
anaesthesia has improved with use of other local anaesthetics like
lignocaine, bupivacaine, tetracaine. Pure isomeric compounds are now
available such as Ropivacaine and Levobupivacaine with favourable
clinical outcome. Ropivacaine produces shorter duration of motor block
than levobupivacaine which is useful in the early mobilization of the
patient and hospital discharge.
Ropivacaine is a first single enantiomer specific compound, which
has a reduced risk of cardiotoxicity, neurotoxicity, and rapid recovery of
motor function. Postoperative pain relief is an important issue with
Ropivacaine.  So,  our  concern  is  of  using  a  drug  as  an  adjuvant  with
Ropivacaine which provides better intraoperative haemodynamic
condition as well as prolonged postoperative analgesia with minimal side
effects.
2Regionally applied opioids are effective analgesics used since
middle of  nineteen’s century when morphine was injected perineurally
The first report on  intrathecal opioid anaesthesia was published in 1901
and on epidural morphine in 1979. Besides morphine various other
opioids and adjuvants have been introduced to improve the efficacy of
neuraxial analgesia, including NMDA antagonists (ketamine,
magnesium), GABA agonists (midazolam) and adrenergic agonists
(clonidine, adrenaline), COX-inhibitors (ketorolac), Ach-esterase
inhibitor (neostigmine) etc.
An ideal adjuvant should provide a longer duration of analgesia
and better hemodynamic stability. ?-2 adrenergic agonists as an
intrathecal adjuvant have excellent analgesic and  minimal sedative
properties (2-6). Dexmedetomidine which is a highly selective ?-2
adrenergic agonist with eight times greater affinity for receptors than
clonidine. The requirements of analgesia are greatly reduced to a large
extent by the use of the above mentioned adjuvants because of their
unique analgesic properties. They also augment the effects of local
anaesthetics by causing  hyperpolarisation of nerve cells and alters the
transmembrane potential and conduction of ion in the brain stem (Locus
Coerulues) (11, 17, 18, 23, 24). These are useful pharmacological agents that
reduces the requirements of other analgesics and by providing better
hemodynamic stability (26) .
3          With the knowledge of pharmacological properties and drug
interactions we designed a prospective randomised controlled study in a
double blinded manner at our institution for the patients receiving spinal
anaesthesia who underwent lower limb orthopaedic surgeries. Our aim
was to compare the duration of analgesia, duration of sensory and motor
blockade and incidence of side effects of intrathecal 0.75% isobaric
ropivacaine with combination of 0.75% isobaric ropivacaine and
dexmedetomidine.
4ANATOMY OF SUBARACHNOID SPACE
Transverse secton of  an intervertebral disc
Vertebral column
The vertebral column comprises of 33 vertebrae (7 cervical, 12
thoracic, 5 lumbar, 5 fused sacral,and 4 coccygeal), has four curves. The
cervical and lumbar curves are convex anteriorly, the thoracic and sacral
curves posteriorly. These curve have a significant infulence on the spread
of local anaesthetics in the subarachnoid space. The vertebal column is
bound together by several ligaments which give it stability and elasticity.
5They  are
1. Supraspinous ligament – strong fibrous cord connects the apices of
spinous processes from sacrum to C7, and then extended to
external occipital protruberance as the ligamentum nuchae.
2. Inter spinous ligament – thin membranous ligament connects the
spinous processes, blend anteriorly with ligamentum flavum and
posteriorly with supraspinous ligament.
3. Ligamentum flavum – also called as ‘yellow ligament’, comprises
of yellow elastic fibres and connects adjacent lamina that runs from
the caudal edge of the vertebra above to the cephalad edge of the
lamina below.
4. Longitudial ligaments – the anterior and posterior longitudinal
ligaments bind vertebral bodies together.
The spinal cord continues above with the medulla oblongata,
begins at the level of the foramen magnum and ends below as the conus
medullaris. It is cylindrical in shape, 45 cm in length in adults, flattened
in the lumbar region. A thin thread, filum terminale is attached to the
coccyx. At birth it ends at the lower border of L3 and rises to end in adult
life at the lower border of L1.
There are totally 31 pairs of symmetrically arranged spinal nerve
roots:  Cervical 8, Thoracic 12, Lumbar 5, Sacral 5and Coccygeal 1. The
cauda equina is formed by elongation of nerve roots of lumbar and sacral
region before they exit from the intervertebral foramen.
6Saggital section of spinal cord termination
The central nervous system is protected and supported by 3
different membrane coverings called meninges. Outer most membrane is
the duramater, innermost is the piamater and arachnoid membrane is in
between. The potential space between the duramater and arachnoid mater
is called subdural space, and space between the arachnoid mater and pia
mater is called sudarachnoid space.    Extradural (epidural) space is above
the duramater.
7SPINAL CORD STRUCTURES
1. Epidural (extradural) space – between the dura mater and the
periosteum. It extends from the foramen magnum to the sacral
hiatus. It is a triangular space in cross-section, with two larger
postero lateral and a small anterior compartments. It also extends
through the spinal foramina (as the nerve roots exit) laterally. The
depth  of  the  epidural  space  is  at  3–5  cm  beneath  the  skin.  The
extradural space consists of adipose tissues, lymph vessels, arteries
and venous plexus (valveless, vertebral, venous plexuses of
Bateson – forming a communication between pelvic and cerebral
veins)
2.  Subdural space – a potential between the arachnoid mater and the
duramater which contains thin serous fluid.
3. Subarachnoid space - space between the arachnoid mater and
piamater contains cerebrospinal fluid (CSF), spinal nerves, a
trabecular network between the two membranes, blood vessels that
supply the spinal cord and lateral extensions of the piamater and
dentate ligaments, which provide lateral support from spinal cord
to the duramater. Although the spinal cord ends at the lower border
of L1 in adults, the subarachnoid space continues to S2.
4. Dura mater – contains two layers of dense fibro elastic membrane
in which the outer layer attaches to the foramen magnum and the
8inner layer continues from the cerebral dura. The dura ends at the
second sacral segment (variably L5–S3). It attaches to the
coccygeal periosteum and covers the filum terminale. Anteriorly
the dura is attached to the posterior longitudinal ligament and
extends around the nerve roots laterally but it is free posteriorly.
5. Arachnoid mater – delicate, nonvascular thin membrane closely
lining the duramater. Arachnoid functions as the principal barrier to
drugs crossing in and out of the CSF and is estimated to account
for 90% of resistance to the drug migration.
6. Pia mater – highly vascular connective sheath that closely covers
the spinal cord. The anterior part is thickened (linea splendens) and
attached to the dura laterally (ligamentum denticulatum).
Posteriorly it attaches to the dura by an incomplete sheet of pia
(posterior subarachnoid septum). The inferiorly it is attached to the
coccyx is through filum terminale which is its continuation.
9CEREBROSPINAL FLUID (CSF)
Cerebro spinal fluid circulation
Cerebrospinal fluid is an ultrafiltrate of the blood plasma, with
which it is in hydrostatic and osmotic equilibrium. It is clear, colourless
fluid found in the spinal and cranial subarachnoid spaces and in the
ventricles of the brain.
? Volume – total volume is 150 ml and only 25 ml is present in
spinal/subarachnoid space.
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? Production – it is produced by the choroid plexuses of the two
lateral, third and fourth ventricles. It circulates via the paired
interventricular foramina (of Munro) from the two lateral ventricles
to the 3rd ventricle, and to the 4th ventricle via the cerebral
aqueduct. The CSF then flows through the paired lateral foramina
of Lushka and the median foramen of Magendie from the 4th
ventricle to the subarachnoid space
? Absorption – 80% is absorbed via the projections of arachnoid
mater (arachnoid villi) in the cerebral venous sinuses. The
remaining 20%is absorbed by arachnoid villi in spinal cord or by
lymphatic drainage.  The CSF pressure ranges from 6 to 10 cm of
CSF (60 – 80mm H?O) when lying and 20–40 cm in the lumbar
area when sitting and it is gravity-dependent.
? Composition – it is composed of
Glucose  = 1.5–4.0 mmol/L,
Sodium = 140–150 mmol/L,
Chloride = 120–130 mmol/L,
Bicarbonate = 25–30 mmol /L,
Protein =  0.15–0.3 g/L,
Cells =  < 5 lymphocytes/cubic mm,
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Osmolality =  280 mOsm
Specific gravity =  1006 (1003 – 1009) at temperature 37°C,
pH = 7.4,
Pco? = 48mmHg.
Action of local anaesthetics
Local anaesthetic prevents the sodium channel activation by
binding to Na+ channels in the inactivated state. Development of the
action potential is prevented by blocking the movement of Na+ into the
cell. Membrane stabilization property is unique quality of the local
anaesthetics where the repeated nerve stimulation will not affect the
resting membrane potential.
Mechanism of action of local anaesthetics in neural blockade
In the dorsal horn neurons, local anaesthetics block both ion
channels (Na+ and K+) inhibiting the generation of nociceptive electrical
activity and propagation of pain (noxious) signals. Similarly it acts on the
ventral horn neurons to produce the motor blockade. Centrally
administered local anaesthetics produces an intense analgesic action by
blocking the Ca+ channels in the spinal cord. This may lead to resistance
of electrical stimulation from afferent nerves carrying pain signals. Apart
from these actions local anaesthetics given through intrathecal route
indirectly inhibit neurotransmitters release like substance P involved in
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pain signal processing. Along with substance P, centrally given local
anaesthetics blocks the presynaptic voltage-gated Ca+ channel. This leads
to blockade of neurotransmitters  like glutamate, substance P, calcitonin
gene-related peptide (CGRP), neurokini-1 and -2 (NK1, NK2) at the
presynaptic level. Therefore local anaesthetics given in spinal
(intrathecal) can indirectly inhibit the transmission of pain signal.
Order of blockade in spinal
The block and recovery of sensory fibers occur in this order
Preganglionic sympathetic fibers (B-fibers) are the most sensitive to local
anaesthetic
C fibers – cold sensation
A ? fibers – pin-prick
A ? fibers – touch
Vibration and proprioception
Motor fibers A? are less sensitive to local anaesthetic
Spinal anaesthesia merits and demerits
Merits of spinal anaesthesia
? Perfoming the spinal is easy
? Reliable block
? Good operating conditions for the surgeon
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? Cost effective
? No airway compromise and minimal respiratory complications
? Faster recovery of gastrointestinal function post operatively
? There is reduction in deep vein thrombosis due to early ambulation
Demerits of spinal anaesthesia
? Failure due to faulty technique.
? Alterations in hemodynamic status is present.
? Resuscitation medications should be available.
? Surgery of longer duration
Factors postulated to be related to spinal anaesthetic block height
Patient factors
? Age
? Height
? Weight
? Gender
? Intra-abdominal mass due to increase in pressure
? Anatomical defects of the spinal column (kyphosis, scoliosis)
? Posture
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Technique of injection
? Site of needle placement – higher the level will affect the block
level .
? Needle angulation – angled cephalad – increase cephalad spread of
hyperbaric solutions injected in lateral position
? Direction of bevel
? Turbulence in CSF (e.g. by barbotage)
? Rate of injection
Characteristics of spinal fluid
? Volume - Decreased CSF volume leads to higher block level and
vice versa
? Pressure (cough, strain, valsalva maneuver)
? Density – hypobaric local anesthetics may not spread far. But
hyperbaric solutions will result in a greater spread.
Characteristics of local anaesthetic (LA) solution
? Density of Local anaesthetic solution – L.A weight vs. CSF weight.
? Specific Gravity – density of a local anaestheic solution compared
to the density of water.
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? Baricity - the ratio of the density of local anaesthetic solution to
density of CSF
? Amount (mass)
? Concentration - the higher the concentration, the higher the block.
? Temperature - cold solution are viscous which limits its spread.
Increase in the temperature of the solution increases the spread. It
is a minor consideration.
Volume –increase in volume, greater will be the spread.
Vasoconstrictors
Distribution of L.A in CSF
Factors with proven effects
? Site of injection
? Anatomic configuration of spinal column
? Patient height (only at extremes)
? Angulation of needle
? Volume of CSF (e.g. ? CSF vlume with ?intra-abdominal pressure
(e.g. pregnancy)
? Characteristics of L.A. solution – Density, Specific gravity,
Baricity.
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? Dose of L.A solution
? Volume of L.A. solution
? Position of patient during injection
? Position of patient after injection
Factors with no proven effects
? Patient weight
? CSF composition
? Circulation of CSF
? Concentration of L.A. in solution injected
? Diffusion in CSF, independent of baricity
? Addition of vasoconstrictors
? Direction of needle bevel during injection
? Rate of injection
? Turbulence in CSF (barbotage)
? Coughing, straining, labour pain
? Age
? Gender
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PHARMACOLOGY
ROPIVACAINE
Ropivacaine hydrochloride
(S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
hydrochloride
Stucture of Ropivacaine
Molecular Formula C17H26N2O2.HCl.H2O: Molecular Weight 328
Ropivacaine is amide type local anaesthetic drug with both
anaesthetic and analgesic properties. At high doses it produces
anaesthesia and at lower doses it produces analgesia (sensory block) due
to its differential blocking effect on nerve fibres. It belongs to different
local anaesthetic group, the pipecoloxylidides, which was synthesized in
1957.
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Ropivacaine, a local anaesthetic with increased duration of action,
which is similar in structure to Bupivacaine. In contrast to Bupivacaine,
Ropivacaine a pure S (-) enantiomer, has reduced toxicity and at the same
time improved sensory and motor block. It acts on different ion channels
like sodium, potassium, and calcium with different affinity that leads to
greater reduction in neuronal toxicity and cardiovascular side effects.
Ropivacaine is derived as a pure form of S (-) enantiomer from
propivacaine, the parent molecule with chiral property. It is a
pipecoloxylidides group of local anaesthetics with the piperidine nitrogen
atom having a propyl group.
Ropivacaine causes reversible blockade of impulse propagation by
inhibition of sodium ion influx in nerve fibres. It inhibits the potassium
channels in dose-dependent manner. Because of less lipid solubility than
bupivacaine, it minimally penetrates the large myelinated A? motor
fibres, this explains its more specific action on the pain-transmission
through A? and C nerves rather than A? fibres (motor function).
Ropivacaine has fewer propensities for cardiac and CNS adverse
effects because of its stereo selective property. It has similar efficacy of
levo bupivacaine and Bupivacaine in blocking peripheral nerve. When
given neuraxially (epidural or intrathecal) it is less potent than
bupivacaine. It is associated with incidence of lower grade motor
blockade when compared to bupivacaine. Because of its lower grade
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motor blockade, reduced potential for CNS and cardiac adverse effects it
is new agent of choice for regional anaesthesia.
PHARMACOKINETICS(30)
               The plasma concentration varies depends on the dose, route of
administration and injection site vascularity. Ropivacaine follows linear
pharmacokinetics Cmax is proportional to the dose. When given
extradural its absorption is biphasic (t1/2 is 4mins and 4 hrs) and
complete. Elimination of ropivacaine is mainly depends on absorption
which is a rate limiting step. Epidurally given drug has longer t1/2
compared to intravenous route. The terminal half life of ropivacaine is
1.8hrs after IV route.
                Ropivacaine is highly protein bound particularly to ?1-acid
glycoprotein and only 6% present as unbound fraction. It crosses easily
through the placenta and degree of plasma protein binding in fetus is less
compared to mother.
METABOLISM
              It is metabolized mainly by aromatic hydroxylation particularly
in liver. If given IV, large doses are excreted via urine for about 86% out
of which only 1% is unchanged fragment. The main metabolite is 3-
hydroy-ropivacaine is excreted after conjugation. Other metabolites like
4-hydroxy-ropivacaine,the N-dealkylated metabolite 2’, 6’-
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ipecoloxylidide and 4-hydroxy dealkylated are present only in minimal
quantities in plasma. Similar kind of kinetics is present in children more
than 1 year. The PPX (2’, 6’-pipecoloxylidide) has longer t1/2 and lower
clearance after infusion through epidural.
? Clearance – unbound ropivacaine – 13.94L/h/Kg
? Clearance – Total ropivacaine – 0.555L/h/Kg
? Volume of distribution – 65.57L/min
? Terminal t1/2 of ropivacaine - 3.3hrs
? Terminal t1/2 of PPX – 17.8 hrs
CONTRAINDICATIONS
? Hypersensitivity to any amide type local anaesthetic.
? Not recommended where faster onset of surgical anaesthesia is
required.
? Intravenous regional anaesthesia.
? Paracervical block in obstetric anaesthesia.
? Hypovolemia.
? Premature children.
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PRECAUTIONS
? Accidental intravenous administration results in cardiac arrest and
convulsions.
? Retrobulbar block because of less clinical evidence.
? Patient with poor general condition
? Liver disease.
? Kidney dysfunction.
? Acute porphyria
DRUG INTERACTIONS
? Duration and intensity of block will not be altered by adding
adrenaline.
? Additive effects with other local anaesthetics.
? Other anti-arrhythmic drugs.
? Used with potent enzyme inhibitors like fluvoxamine, verapamil
will prolong the half life.
? Used with ketaconazole reduces the plasma clearance by 15 %.
INDICATIONS
? Epidural block for surgical anaesthesia for abdominal surgeries,
pelvic, lumbar and lower limb, Caesarean section.
? Paediatric caudal block
? Spinal anaesthesia.
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? Nerve blocks.
? Field and filtration blocks.
DOSAGE AND ADMINISTRATION
? Caudal – 1mg/kg, 0.2% or 2mg/ml produces a level below T12.
? Epidural block with 6-14 ml of 0.2% ropivacaine provide adequate
analgesia.
? Spinal – 2-3ml of 0.75 %( 7.5mg/ml) with doses between 15-
22.5mg results in sensory block upto T4 or T5
Surgical
anaesthesia
Concentration
mg/ml
Volume
(ml)
Dose
(mg)
Onset
(minutes)
Duration
(hours)
Lumbar
epidural,
pelvic, and
lower limb
surgeries
5.0
7.5
15-30
15-25
75-150
113-188
15-30
10-20
2-4
3-5
Nerve blocks 5.0
7.5
35-50
10-40
175-250
75-300
15-30
10-25
5-8
6-10
Field block 5.0
7.7
1-40
1-30
5-300
7.5-225
1-15
1-15
2-6
2-6
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PREGNANCY AND LACTATION
No well controlled studies in pregnant and nursing mothers.
ADVERSE EFFECTS
? Hypersensitivity reactions
? Main effects-Hypotension, bradycardia, vomiting, urinary
retention, raised body temperature, rigors, back pain.
? Less common effects – CNS toxicity, cardiac toxicity
? Spinal cord dysfunction such as anterior spinal artery syndrome,
arachnoiditis, cauda equina syndrome.
Other effects
It has some antibacterial properties and some action on inhibition
of platelet aggregation
INTRATHECAL ADMINISTRATION
Ropivacaine is less potent than bupivacaine in equal volume of
doses of similar concentration . Hyperbaric solutions has faster onset and
more reliable block with good recovery.because of the variability in
spread and duration of the block hyperbaric Ropivacaine solutions are not
available commercially. When administered with opioids ropivacaine not
only reduces the total dose of local anaesthetic  but also causes significant
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prolongation in the duration of complete and effective analgesia without
increase the duration of motor block.(3)
A research on lower limb surgeries with 15 mg of Ropivacaine was
found to be equipotent with 10mg of Bupivacaine with respect to sensory
block but not for the motor block which was significantly of shorter
duration. The potency of Ropivacaine relative to Bupivacaine is 2/3rd
with regard to sensory block and ½ with regard to motor block(4).
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PHARMACOLOGY OF ?-2 AGONISTS
HISTORY
Historically ?2-agonists have been used in treating hypertensive
patients and for withdrawl symptoms in alcohol and drug abusers. ?2-
agonists provide sedation, antianxiety, hypnosis, analgesia and also
inhibit sympathetic system.
Dexmedetomidine is more selective ?2 agonist with 1600 greater
selectivity for ?? receptor compared with ?? receptor. It was introduced in
1999  as  a  short  term  sedative  agent  in  ICU  for  adult  patients  on
mechanical ventilator. But now it is widely used as sedative, adjunct
analgesia for various diagnostic procedures.
PHYSIOCHEMICAL CHARACTERISTICS(29)
Dexmedetomidine is the d-enantiomer of medetomidine. It belongs
to imidazole subgroup of ?2 agonist. The receptor specificity ratio
1600:1(??: ??). It is freely soluble in water.
Structure of Dexmedetomidine
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Physiological functions of ? 2 receptors
? 2a – presynaptic feedback inhibition of norepinephrine release
Hypotension
Analgesia
Sedation
Inhibition of epileptic seizures
? 2b –hypertension
Placental angiogenesis
          Analgesic effect of nitrous oide
? 2c –feedback inhibition of adrenal catecholamine release
           Analgesic effect of moxonidine
             Modulation of behaviour
Mechanism of action
1. Activate inhibitory action of G proteins leading to decrease in
cyclic AMP.
2. Activate G proteins which directly act on membrane bound ion
channels, particularly potassium channels.
3. Activate Nitric Oxide, cyclic GMP pathway by inhibiting the
release of noradrenaline within neuronal tissue.
In the dorsal motor complex of medulla it causes hypertension and
bradycardia. Action on locus coeruleus leads to sedation and analgesia.
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There is high density of receptors in the vagus nerve, intermediolateral
column and the substantia gelatinosa, dorsal horn of the spinal cord and
Primary sensory neurons.
?2 adrenoceptors
?2receptors are G-protein-coupled receptors in the
transmembrane region of the central and peripheral nervous system
particularly at autonomic ganglion of presynaptic and post-synaptic
region. Nor epinephrine (Endogenous agonists) and clonidine (exogenous
agonists) acts on these receptors inhibit the enzymes  adenylyl cyclase
and phospholipase C  resulting in the inhibition of calcium ion (Ca+)
entry and facilitation of opening potassium ion (K+) channels outwards
that results in hyperpolarization.
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Structure of ?2-adrenoceptors
29
Possible mechanism of action of ?2-adrenoceptors
Pre-synaptic activation of ?2-adrenergic receptors in sympathetic
nerve endings and noradrenergic neurons inhibit norepinephrine release.
In Central nervous system it leads to inhibition of sympathetic activity,
resulting in hypotension, bradycardia and sedation. However, at higher
doses it produces hypertension through receptor activation present on
smooth muscle cells of the resistance vessels. The hypnosis is mediated
through ?2-receptors of the locus coeruleus, analgesia is mediated by ?2-
adrenoceptors of spinal cord. Imidazole ring of the ?2-agonist drugs may
interact with imidazoline receptors. Clonidine and Dexmedetomidine
(Dex) belong to imidazoline compounds.
Pharmacokinetics
Dexmedetomidine is rapidly distributed and extensively
metabolized in liver and excreted in urine and feces. It undergoes
conjugation (41%), n-methylation (21%), or hydroxylation followed by
conjugation. It is 94% protein bound to serum albumin and ?1-
glycoprotein, hence  has a volume distribution of approximately 200 litres
and its concentration ratio between whole blood and plasma is 0.66. It
displays nonlinear pharmacokinetics and best described by three
compartment  model.  The  elimination  half  life  is  2  to  3  hours,  with  a
context sensitive half life of 4 mins after 10 mins of infusion to 250 mins
after an 8 hour infusion.
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Dexmedetomidine after IV exhibits the following
pharmacokinetics: a rapid distribution phase with half-life (t½) of 6
minutes; elimination t½ of about 2 hours; and volume of distribution at
steady-state (Vss) of around 118 litres. Clearance is about 39 L/h for a 72
kg person.
Distribution
Dexmedetomidine bind to plasma protiens of 94% which is
constant for different concentration in plasma which is similar for both
sexes. Patients with decompensated liver disease have decreased binding
to plasma proteins.
Dexmedetomidine hydrochloride displaces, fentanyl, ketorolac,
digoxin, theophylline and lidocaine from protein binding in laboratory
settings. In vitro the displacement of the drugs like ibuprofen, phenytoin,
warfarin, propranolol, digoxin and theophyllin are not significant.
Metabolism
There is almost complete biotransformation of dexmedetomidine
with very little unchanged amount is excreted in urine and feces.
Biotransformation occurs via both direct glucuronidation as well as
cytochrome P450 mediated metabolism.
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The major metabolic pathways are
1.  Direct N-glucuronidation to inactive metabolites;
2. Aliphatic hydroxylation (mediated primarily by CYP2A6) to 3-
hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-
dexmedetomidine, and 3-carboxydexmedetomidine
3. N methylation of dexmedetomidine to generate 3-hydroxy N-
methyl-dexmedetomidine, 3-carboxy N-methyl-dexmedetomidine,
and dexmedetomidine-N-methyl O-glucuronide.
Elimination
The dexmedetomidine has terminal elimination half-life (t½) of
approximately 2 hours and clearance estimated to be approximately 39
L/h
Age and Gender
Dexmedetomidine hydrochloride does not show any variation in
pharmacokinetics in both the sexes and in all age groups.
Pediatrics
The researches are minimal in children regarding the
pharmacokinetics.
Hepatic Impairment
Hepatic clearance values are lower depends on degree of hepatic
derangement. It is necessary to reduce the dose in patients with hepatic
derangement depending on variations in liver function test.
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Renal Impairment
Dexmedetomidine hydrochloride pharmacokinetics (Cmax, Tmax,
AUC, t½, CL, andVS) do not vary in patients with severe renal
impairment (creatinine clearance: < 30 mL/min) compared to healthy
subjects. Since the metabolites are excreted in urine they may accumulate
on long term infusion.
Drug Interactions
No evidence of cytochrome P450 mediated drug interactions that
are likely to be of clinical relevance. Co-administration with anaesthestic,
sedatives, hypnotics or opioids may lead to enhancement of their effect.
These drugs may require reduction of dose. It may have additive effect
with vasodilator and negative chronotrophic agents. Midaolam and
propofol co administration may lead to increased incidence of
bradycardia and hypotension hence require more caution.
Pregnancy,Labour and Lactation
There were no adequate and well controlled trials. Hence should
used with caution.
Adverse effects
Most frequently observed side effects are hypo or hypertension, dry
mouth, bradycardia and nausea. Other side effects are fever, arrhythmias,
AV block, extra systoles, pulmonary oedema, dizziness, headache etc
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Alpha 2 antagonist
Atipamezole
Atipamezole, a selective a2-adrenoceptor antagonist readily
reverses the sedative properties of Dexmedetomidine. Intravenous
atipamezole reverses the sedation and sympatholysis in dose-dependent
manner. Because of the similar elimination half-lives of both agonist and
the antagonist, the clinical effect of Dexmedetomidine after reversal by
atipamezole is very minimal. Therefore the dexmedetomidine provides
hypnosis and sedation in titrated doses and reversed easily by
atipamezole.
34
REVIEW OF LITERATURE
1. Kallio H et al(11) (2004) had conducted a prospective randomized
double-blinded study in 90 patients who had undergone lower limb
surgeries. They had received 2ml of 1% ropivacaine (20mg),
0.75% ropivacaine (15mg), or 0.5% bupivacaine (10mg) in spinal
anesthesia. They assessed the motor block with the modified
Bromage scale, and pinprick to assess the sensory block.
Ropivacaine 15 mg had a shorter duration of motor block (150
mins) than bupivacaine 10 mg (210 min; P = 0.005), but they did
not differ significantly in the median duration of motor block at
T10 (140 min) for both groups. There was a significantly longer
duration of sensory block at T10 with ropivacaine 20 mg (170 min)
than with bupivacaine 10 mg (140 min; P = 0.005), but they did not
differ significantly in the median recovery from sensory block (210
min).   They  concluded  that  the  duration  of  sensory  block  of
ropivacaine was only two thirds and the motor block duration was
half when compared with bupivacaine, based on the duration-per-
mg of the local anesthetic agent.
2. Antonio Mauro Vieira et al (3) (2004) conducted a study to
evaluate the analgesia and sedation promoted by clonidine or
dexmedetomidine associated to epidural ropivacaine in the
postoperative period of subcostal cholecystectomy. Clonidine and
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dexmedetomidine are ?-2-adrenergic agonists with analgesic
proprieties which potentiate local anaesthetic effects when
epidurally administered. Forty patients of both gender were
participated in this randomized double-blind study, aged 18 to 50
years, weighing 50 to 100 kg, physical status ASA I or II,
submitted to subcostal cholecystectomy. The subjects were
distributed in two groups: Clonidine (CG) received clonidine (1
mL = 150 ?g) associated to 0.75% epidural ropivacaine (20 mL);
Dexmedetomidine (DG) received dexmedetomidine (2 ?g/kg)
associated to 0.75% epidural ropivacaine (20 mL). Analgesia and
sedation were evaluated 2, 6 and 24 hours after anesthetic recovery.
Both groups presented some grade of sedation at 2 and 6 hours,
with statistically significant difference between the two moments
for the dexmedetomidine group. There has been analgesia in both
groups, especially at 2 and 6hours. There has been statistically
significant difference among periods of 2, 6 and 24 hours in the
dexmedetomidine group; in the clonidine group, this statistically
significant difference was observed between the periods of 2 and 6
hours and between 2 and 24 hours. To conclude that the association
of clonidine or dexmedetomidine to 0.75% ropivacaine induces
analgesia and sedation in 2 and 6 hours after anaesthetic recovery
in patients submitted to subcostal cholecystectomy and that
clonidine promotes more prolonged analgesia.
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3. Kanazi GE et al (19) (2006) in a prospective double-blind study in
60 patients who were randomly allocated into group B
(bupivacaine 12mg), group C (bupivacaine 12mg + 30 ug of
clonidine and group D (12 mg of bupivacaine + 3ug of
Dexmedetomidine) underwent transurethral prostatic resection and
bladder tumour resection under spinal anaesthesia. They had
compared the onset and duration of sensory block and motor block,
heart rate and blood pressure changes and sedation. They had
found longer sensory and motor regression in patients in groups D
and C which was significant and significantly shorter onset time of
motor block than patients in group B. The mean time regression of
sensory level to the S1 segment was 190 +/- 48 minutes in group B,
272 +/- 38 minutes in group C and 303 +/- 75 minutes in group D
(P < 0.001). The regression time of Bromage 0 was 163 +/- 47
minutes in group B, 216 +/- 35 minutes in group C and 250 +/- 76
minutes in group D (P < 0.001). Patients belong to groups D and C
did not show significant difference in the onset and regression
times. There was no significant difference in the hemodynamic
variability and level of sedation in all the three groups during intra-
operative and post-operative period. They concluded that
Dexmedetomidine (3ug) or clonidine (30ug), given with intrathecal
bupivacaine, produces a longer duration of the motor block and
sensory block, stable hemodynamics and minimal sedation.
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4. Al-Mustafa MM et al (21) (2009) assigned 60 patients and studied
the effect of adding dexmedetomidine to bupivacaine for neuraxial
anesthesia. They were randomly divided into 3 groups, group N
(bupivacaine 12.5mg with normal saline), group D5
(Dexmedetomidine 5 ug), or group D10 (Dexmedetomidine 10 ug).
The onset time to reach dermatome T10 level and modified
Bromage 3 grading of motor blockade, and the time to S1 segment
regression and modified Bromage 0 grade of motor blockade were
recorded.  The  mean  time  to  attain  the  sensory  level  of  T10
dermatome was 9.5 +/- 3.0 minutes in group N, 6.3 +/- 2.7 minutes
in group D5 and 4.7 +/- 2.0 minutes in D10 group. The mean time
to reach complete motor blockade (modified Bromage 3 scale) was
18.0 +/- 3.3 minutes in group N, 13.0+/-3.4 mins in D5 and 10.4
+/- 3.4 mins in group D10. The regression time to reach dermatome
S1 level was 165.5 +/- 32.9 mins in group N, 277.1 +/- 23.2 mins
in group D5, and 338.9 +/- 44.8 mins in group D10. The regression
to Bromage 0 was 140.1 +/- 32.3 minutes in group N, 246.4 +/-
25.7 minutes in D5 and 302.9 +/- 36.7 minutes in D10. The onset
and regression of both sensory and motor block were statistically
significant (p<0.001). They had concluded that Dexmedetomidine
prolongs the onset and regression time of both sensory and motor
block in a dose dependent manner when given as an intrathecal
adjuvant to bupivacaine.
38
5. Mausumi Neogi et al (14) (2010) had conducted a prospective
randamized study to assess and compare the analgesic efficacy of
clonidine and dexmedetomidine used as adjuvant to ropivacaine for
paediatric patients received caudal analgesia. Seventy five patients
who underwent elective inguinal herniotomy were divided
randomly into three following groups. Group R (1 ml/kg of 0.25%
ropivacaine), Group C (1ml/kg of 0.25% ropivacaine and 1ml/kg
clonidine), Group D (1 ml/kg of 0.25% ropivacaine and 1 ?g/kg
dexmedetomidine). CRIES scale was used to asseess the analgesia
during postoperative period. The duration of analgesia was
6.32±0.46 hrs in group R, 13.17±0.68 hrs in group C and
15.26±0.86 hrs in group D. The duration of analgesia was
significantly prolonged in both the groups C and D in comparison
to group R. The three groups did not differ significantly in the
incidences of side effects. They concluded that both clonidine and
dexmedetomidine when given caudally with ropivacaine
administered significantly increase the duration of analgesia.
6. Gupta R et al (1) (2011) conducted a randomised double blind trial
in sixty patients to study the efficacy and safety of intrathecal
dexmedetomidine added to ropivacaine by giving either 3 ml of
0.75% isobaric ropivacaine + 0.5 ml normal saline (Group R) or 3
ml of 0.75% isobaric ropivacaine + 5 ?g dexmedetomidine in 0.5
ml of normal saline (Group D).They obtained the following results.
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The  mean time of sensory regression to S2 was 468.3±36.78
minutes in group D and 239.33±16.8 minutes in group R. Duration
of analgesia (time to requirement of first rescue analgesic) was
significantly prolonged in group D (478.4±20.9 minutes) as
compared to group R (241.67±21.67 minutes). The maximum score
for  pain  assessed  by  visual  analogue  scale  was  less  in  group  D
(4.4±1.4) as compared to group R (6.8±2.2). They had concluded
that the addition of dexmedetomidine to ropivacaine intrathecally
produces a prolonged duration of analgesia, sensory and motor
blockade.
7. Gupta  R et  al (20) (2011) had studied 60 patients who underwent
surgeries of lower abdomen. They were divided into two equal
groups and received spinal anaesthesia with either 12.5 mg of
bupivacaine with 5?g of dexmedetomidine (group D) or 12.5 mg of
bupivacaine with 25?g of fentanyl (group F). They had studied the
onset and duration of sensory and motor block, changes in heart
rate and blood pressure, duration of analgesia and side effects in
both the groups. They had found that the patients in group (D) had
a longer duration of sensory block and motor block than in group
(F) which was statistically significant. The mean time regression to
S1 segment regression was 476±23 min in group D and 187±12
min in group F which was significant. The duration of motor block
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was 421±21 min in group D compared to group F which was
149±18 min. They had concluded that the dexmedetomidine given
via spinal is associated with longer duration of sensory and motor
block, stable hemodynamics and reduced analgesic usage in first 24
fours.
8. Eid  HEA  et  al(22)  (2011) investigated 48 adult patients who
underwent  reconstruction of anterior cruciate ligament  and were
randomly divided into three groups. Each group of patient has
recieved 3.5 ml volume of drug that consisted of 3 ml hyperbaric
solution  of  0.5%  bupivacaine  and  0.5  ml  of  either  10  ?g
dexmedetomidine (Group D1), 15?g dexmedetomidine (D2) or
normal  saline  (Group  B).  Heart  rate,  blood  pressure,  duration  of
sensory and motor block, pain score, sedation level and incidence
of side effects were recorded during intraoperative and upto 24
hours after intrathecal administration. They found out that there
were statistically significant differences in two segment regression
times, regression time to S1 segment, regression to modified
Bromage  0  and  time  to  first  demand  analgesia.  There  was  a
significant decrease in pain scores postoperatively. The effects
were more  in group D2 than in group D1. Group D2 patients had
more sedation scores and lesser analgesic requirements in the
postoperative period than Group D1 or B. There was no statistical
difference in hemodynamic variability. They had concluded that
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the dexmedetomidine in  different doses of 10 ?g and 15 ?g
prolong the anesthetic and analgesic effects significantly with
spinal bupivacaine in a dose-dependent manner. A 15?g dose
might have significant effects  for complex lower limb surgical
procedures
9. Shukla et al (16) (2011) conducted a prospective randomized
double-blind study in 90 patients who underwent lower abdominal
surgeries. They were randomly allocated in three equal groups and
received 15 mg of spinal hyperbaric bupivacaine with 0.1 ml
(10?g) of dexmedetomidine (group D) or 15 mg hyperbaric
bupivacaine with 0.1 ml (50 mg) magnesium sulfate (group M) or
15mg hyperbaric bupivacaine with 0.1 ml normal saline (group C)
as control.  They had evaluated the onset and duration of sensory
and motor block, duration of analgesia and side effects of
dexmedetomidine and magnesium sulfate given with 0.5%
bupivacaine for spinal anesthesia. They had found that the quicker
onset of anesthesia and longer duration of analgesia in the
dexmedetomidine group (D). They also showed that in group (M)
the onset of block was delayed but significantly prolonged duration
compared to control group (C), but to a lesser in group (D). The
groups were similar with respect to hemodynamic changes and no
significant side-effects in both the groups.
42
10. Vijay.G.Anand et.al(15) (2011)conducted a study to compare the
effects of caudal dexmedetomidine combined with ropivacaine to
provide post operative analgesia in children. The study was
conducted in 60 children who had undergone lower abdominal
surgeries. They were allocated into 2 groups of 30 each. Group RD
received 0.25% ropivacaine 1 ml/kg with dexmedetomidine 2µg/kg
(made up to 0.5ml) and group R received 0.25% ropivacaine
1ml/kg + 0.5 ml normal saline. Induction was done with
50%N2Oand 8% sevoflurane in O2 in spontaneous ventilation and
then LMA was inserted .After that caudal block was performed and
the study drug was given as mentioned above. The duration of post
operative analgesia was recorded and median of 5.5 hrs in Group R
compared  with  14.5  hours  in  Group  RD,  with  a  p  value  of
<0.001.Group R patients achieved and statistically significant
higher FLACC score compared to RD patients. The mean sedation
score, emergence behaviour score, mean emergence time was
statistically highly significant (<0.001).The peri operative
hemodynamics were stable in both groups. To conclude caudal
dexmedetomidine (2µg/kg) with 0.25% ropivacaine 2ml/kg for
paediatric lower abdominal surgeries achieved significant post
operative pain relief that resulted in a better quality of sleep and
prolonged duration of arousable sedation.
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AIM OF THE STUDY
Comparison of duration of analgesia, duration of sensory and
motor blockade and incidence of side effects of intrathecal isobaric
0.75% Ropivacaine and combination of intrathecal isobaric 0.75%
Ropivacaine and Dexmedetomidine for lower limb orthopaedic surgeries
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MATERIALS AND METHODS
The study was conducted at Chengalpattu Medical College
between 2011-2012 with ethical committee approval from the
institution.100 patients were randomly selected based on inclusion
criteria and allocated into two equal groups
Study design: A prospective randomized double-blinded study.
Sample size: 100 patients were selected and allocated in two groups
randomly.
Inclusion criteria
? ASAI & II
? Either sex
? 18-60 years for lower limb Orthopaedic surgery
Exclusion criteria:
? Patient refusal
? Patients who had contraindications for spinal anaesthesia
? Allergy to local anaesthetics
? Cardiac disease
? Hypertension
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Preoperative preparation
Patients, age, body weight and baseline vital parameters were
recorded. History regarding previous anaesthesia, surgery and significant
other co morbid illness, medications and allergy was recorded. Complete
physical examination and airway assessment were done.
In the preoperative period all patients were instructed about the
benefits of spinal anaesthesia and 10-point visual analogue scale. And we
obtained informed consent from all the study group patients.
Premedication
All patients were premedicated with T.Ondansetron and
T.Ranitidine  150  mg at  6  am on  the  day  of  surgery.  They  also  received
T.Diazepam0.2mg/kg orally night before surgery and on day of surgery.
Patients were preloaded with ringer lactate at 15ml/kg.
Materials Used
? Spinal needle (Quincke) 23 or 25G
? 5 Ml syringe
? 4 ml ampoule of 0.75% isobaric Ropivacaine ( Preservative free)
? 1 ml ampoule of 100 ug Dexmedetomidine.
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Monitoring and intravenous access
Continuous ECG and SpO?, automated intermittent non invasive
blood pressure monitoring done. Intravenous access was done using 16 or
18 Gauge venflon and intravenous crystalloid was started.
Procedure
Preoperative heart rate, SpO?, blood pressure was obtained.  Under
strict aseptic precautions with the patients in sitting position subarachnoid
block was performed using 23-25G Quincke needle at L3-4, orL4-5space.
Patients were divided into two following groups randomly by lot method.
Group R: Received 3ml volume of 0.75% isobaric ropivacaine and
0.5ml normal saline.
Group D: Received 3ml volume of 0.75% isobaric ropivacaine and
5µg dexmedetomidine in 0.5ml normal saline.
The consultant who prepared the drug combination did not
participate in the monitoring or assessment of the patient. The person who
perfomed the spinal anaesthesia as well as monitoring was blinded to the
groups the patient belongs to. Injections were given over approximately
10 to 15 seconds. Immediately after completion of the block, patients
were made to the supine position.
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          Heart rate, SpO?, blood pressure were recorded every 5min for 30
min following subarachnoid block and every 10min there after till surgery
finishes. Oxygen 4L/min was administrated through a face mask.
Hypotension defined as a decrease in mean arterial pressure more than
30% from baseline or less than 80 mm Hg was treated with incremental
intravenous  (IV)  doses  of  ephedrine  6  mg  and  boluses  of  IV  fluid  as
required. The incidence of adverse effects such as nausea, vomiting,
shivering, itching, pruritus, respiratory depression, sedation and
hypotension was recorded.
          Sensory level was assessed using loss of pinprick sensation and
dermatomal level was tested every 2 minutes until the highest level had
stabilised for 4 consecutive tests. Testing was done every 10 minutes until
the  point  of  two  segment  regression  of  the  sensory  level.  Testing  was
performed by an anaesthetist who was blinded to the patient group.
Testing was continued every 20 minutes until the recovery of S1
dermatome.
Motor block was assessed using modified Bromage scale
? 0 - no motor block,
? 1 - Inability to lift the extended legs, but can bend knees and feet
? 2 - Inability to lift extended leg and move knee, but can move feet
? 3 – full motor block of the limb
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The surgeon and the observing anaesthetist were blinded to the
patient groups. Data regarding the highest dermatomal level of sensory
blockade, the time to reach the highest sensory level from the time of
injection, time to S1 sensory regression and incidence of side effects were
collected.
Four-point verbal rating scale was used to assess the sedation
(1 = no sedation, 2=light sedation, 3=somnolence,
4= deep sedation).
Assessment of Pain using visual analogue score
The pain was assessed using visual analogue scale was used to
assess rating from 0 to 10 during introperative period
Post operative Monitoring
Postoperatively, pain scores were recorded by using VAS between
0 and 10 (0 = no pain, 10 = the most severe pain), initially every 1 hour
for 2 hours, then every 2 hours for next 8 hours and then after every 4
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hours till 24 hours. Injection Diclofenac 75 mg intramuscular was given
as rescue analgesia when VAS ?4.
Recording of adverse effects
During the intraoperative and postoperative period, adverse events
like nausea, vomiting, shivering, dry mouth were noted. Nausea,vomiting
were managed with 4mg of ondansetron intravenously. Shivering was
treated with Inj. Tramadol 100mg slow IV.
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OBSERVATIONS AND RESULTS
The following observations were made and datas were collected
? Heart Rate, Blood pressure, SpO? every 5 minutes until 1 hour and
at every 15 minutes for next one hour and then every 60 minutes
for next 22 hours. Hypotension (defined as fall in systolic arterial
pressure less than 90mmHg) was managed with inj.Ephedrine 6mg
and bradycardia (pulse rate <50 /min) was treated with 0.3mg of
inj.Atropine.
? Time to achieve maximum sensory block in minutes
? Time to two segment regression from highest sensory level in
minutes
? Duration of motor blockade in minutes
? Duration of analgesia in  minutes
? Highest VAS score
? Incidence of side effects
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STATISTICAL ANALYSIS
Data were analysed using INSTAT 3 (Graph Pad Software,
California, USA).Two sided independent  student' s t tests to analyse
continuous data, Fisher's exact test and chi-square test for categorical data
were used. P<0.05 was considered as statistically significant.
RESULTS
DEMOGRAPHIC DATA
The two groups were comparable with  respect to their age, weight,
sex and ASA Physical status. There was no statistically significant
difference among two groups   in demographic profile.
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AGE (student’s t test)
No. of cases Mean ± S.D p value
Group R 50 41.92± 11.65 0.0032
Group  D 50 48.98±8.816
The mean age in years was 41.92± 13.03 in Group R and 48.98±
9.68 in Group D. There was statistically significant difference between
two groups (P<0.05).
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WEIGHT (student’s t test)
No. of cases Mean ± S.D p value
Group R 50 58.8±6.2 0.4840
Group  D 50 57.9± 6.6
The mean weight in kgs was 58.8± 6.2 in Group R and 57.9± 6.6 in
Group D.  Both the groups did not differ significantly (P>0.05).
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Weight in kgs
Weight in kgs
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ASA-PHYSICAL STATUS (Chi-square test)
ASA-PS I ASA- PS II p value
Group R 14(28%) 36(72%) 0.6654
Group D 17(34%) 33(66%)
The percentage of ASAI patient and ASAII patients in Group R
were 28% and  72% respectively while in Group D it is 34% and 66%
respectively. There was no significant difference among both the groups
(P>0.05).
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SEX (Chi-square test)
Female Male P value
Group R 18(45%) 22(55%) 0.8226
Group D 19(43%) 21(57%)
The percentage of female patients and male patients in Group R
were 45% and 55% respectively while in Group D it were 43% and 57%
respectively. They did not differ significantly (P>0.05).
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HIGHEST SENSORY BLOCK OBTAINED(student’s t test)
Level Group R Group D P value
T4 9(18%) 5(10%) 0.8143
T5 3(6%) 0(0%)
T6 28(56%) 42(84%)
/T8 10(20%) 3(6%)
There was no difference in highest  sensory level  obtained in
between two groups. Both group R and group D were comparable in
respect to highest level of sensory block obtained (p value0.8143 i.e
>0.05).
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TIME TO ATTAIN HIGHEST SENSORY BLOCK (student’s t test)
No. of Cases Mean±S.D p value
Group R 50 8.18± 1.7921 0.0001
Group D 50 5.52±2.159
The mean time to attain highest sensory block was 8.18±
1.7921minutes in Group R and 5.52±2.159 minutes in Group D. There
was significant difference among two groups in the time to attain highest
sensory block (P<0.05).
time in min
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TIME TO TWO SEGMENT REGRESSION (student’s t test)
No. of Cases Mean±S.D p value
Group R 50 96± 4.94 0.0001
Group D 50 134±6.06
The mean time for two segment regression was 96 ± 4.94minutes
in Group R and 134 ± 6.06minutes in Group D. There was significant
difference among two groups in the duration two segment regression
(P<0.05).
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DURATION OF REGRESSION TO S1 (student's t test)
No. of Cases Mean±S.D p value
Group R 50 189.1± 23.44 0.0001
Group D 50 423.3± 32.66
The mean duration of analgesia was 189.1± 23.44minutes in Group
R and 423.3± 32.66 minutes in Group D. There was statistically
significant difference among two groups in the duration of  regression to
S1 (P<0.05).
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DURATION OF ANALGESIA (student's t test)
No. of Cases Mean±S.D p value
Group R 50 204.7± 20.61 0.0001
Group D 50 430.9± 33.08
The mean duration of analgesia was 204.7 ± 20.61minutes in
Group R and 430.9± 33.08minutes in Group D. There was statistically
significant difference among two groups in the mean duration of
analgesia (P<0.05).
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DURATION OF MOTOR BLOCKADE (student's t test)
No. of Cases Mean±S.D p value
Group R 50 144.06 ± 18.75 0.0001
Group D 50 271.46 ± 33.40
The mean duration of motor blockade was144.06 ± 18.75 minutes
in Group R and 271.46 ± 33.40 minutes in Group D. There was
statistically significant difference among two groups in the mean duration
of  motor blockade (P<0.05).
Time in min
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FOUR POINT VERBAL RATING SCALE (student’s t test)
Time in
Minutes
No. of
Cases
Group
 R
Group
D P Value
5 50 1 1.08±0.2740 0.0416
10 50 1 2.24±0.4314 0.0001
15-30 50 1 2.765±0.425 0.0001
60 50 1 2.7±0.4529 0.0001
120 50 1 2.52 ±0.504 0.0001
180 50 1 2.5±0.505 0.0001
240 50 1 1.74±0.4646 0.0001
300 50 1 1.64±0.4848 0.0001
360 50 1 1.62±0.4848 0.0001
420 50 1 1.02±0.1414 0.3197
 Sedation as assessed by four point verbal scale was significant
during 10min-360min of the observing period between the two groups
while not significant during first 5mins and after 360min as shown by the
p values.
65
FOUR POINT VERBAL RATING SCALE
VISUAL ANALOGUE SCORE
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VISUAL ANALOGUE SCORE (student’s t test)
Time in
Minutes
No. of
Cases Group R Group D P value
30 50 1.79±1.506 0.125±0.35 0.0001
60 50 3.14±0.78 1.78±0.79 0.0001
120 50 3.18±0.74 2.74±0.44 0.0005
180 50 3.18±0.74 2.74±0.44 0.0003
240 50 3.18±0.74 2.52±0.5 0.0001
300 50 3.18±0.74 2.52±0.5 0.0001
360 50 3.18±0.74 2.72±0.45 0.0003
420 50 4±0 2.42±0.57 0.0001
480 50 4±0 2.88±0.65 0.0001
540 50 4±0 2.92±0.92 0.0001
VAS score between group R and group D were found to be
significant during the whole period of observation (p<0.05).
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SATURATION (Chi-square test)
Intraoperative No. of Cases Mean ± S.D P value
Group R 50 99±0.0047 0.9601
Group D 50 99± 0.0027
Postoperative No. of Cases Mean ± S.D
Group R 50 100±0.00106
Group D 50 99± 0.001118
There was no statistical significant between two groups in
saturation both during intraoperative and postoperative observation
period (p value >0.05).
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INTRAOPERATIVE PULSE RATE (student's t test)
No. of Cases Mean ± S.D p value
Group R 50 90.1± 4.39 0.0001
Group D 50 67.136 ±10.7
The mean heart rate in Group R was 90.1± 4.39 and in Group D
was 67.136 ±10.7, which was found to be statistically significant
(p<0.05).
POSTOPERATIVE PULSE RATE (student's t test)
No. of Cases Mean ± S.D p value
Group R 50 94.25± 2.818 0.0001
Group D 50 60.64 ±0.599
The mean heart rate in Group R 94.25± 2.818was and in Group D
was 60.64 ±0.599, which was found to be statistically significant
(p<0.05).
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MEAN ARTERIAL PRESSURE
INTRAOPERATIVE PERIOD (student's t test)
No. of Cases Mean ±  S.D p value
Group R 50 95.76± 7.45 0.0001
Group D 50 83.04±16.12
The intraoperative mean arterial pressure in Group R was 95.76±
7.45 and in Group D was 83.04±16.12 which was statistically found to be
significant (p<0.05).
POSTOPERATIVE PERIOD (student's t test)
No. of Cases Mean ± S.D p value
Group R 50 109 ± 11.53 0.0001
Group D 50 87.74 ± 4.46
The postoperative mean arterial pressure in Group R was109±
11.53and in Group D was87.74±4.46which was statistically found to be
significant (p<0.05)
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SIDE EFFECTS (Chi-square Test)
Time in
Minutes
No. of
Cases Group R Group D p value
Hypotension 50 6 9 0.5766
Bradycardia 50 3 7 0.3178
Nausea 50 7 3 0.3178
Vomiting 50 7 3 0.3178
Shivering 50 19 2 0.0002
Dry mouth 50 3 3 1.0000
The incidence of hypotension in Group R was 12% and in Group D
was 18% which was statistically not significant (p>0.05).
The incidence of bradycardia in Group R was 6% and in Group D
was 14% and there was statistically no significant difference in both
groups (p>0.05).
The incidence of nausea and vomiting in Group R 14%  and in
Group D was 6% which was statistically not significant (p>0.05)
The incidence of shivering in Group R was 38% and in Group D
was 4% and there was statistically significant difference in both groups
(p<0.05).
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The incidence of dry mouth in Group C was 6% and in Group D
was 6%. Statistically there was no significant difference in both groups
(p>0.05).
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DISCUSSION
An ideal adjuvant should provide a longer duration of analgesia
and better hemodynamic stability. There is a reduced requirement of
analgesia with the use of intrathecal adjuvants due to the property of
augmentation of local anaesthetic effects, thereby prolonging the duration
of analgesia. To avoid neuraxial opioid induced adverse effects such as
respiratory depression, nausea, vomiting, urinary retention and pruritus(25 -
27) , ?-2 agonists are being used as an alternative intrathecal adjuvants.
Introduction of this newer agent dexmedetomidine has increased the
wider scope of ?-2 agonists usage in neuraxial blockade. Rapid onsets of
local anaesthetics action, longer period of analgesia and better
cardiovascular parameters have increased the wider scope of usage of
dexmedetomidine in intrathecal use.
In our study 5µg of dexmedetomidine (made upto 0.5ml with
normal saline) was added to 3ml of 0.75% Ropivacaine or 3ml of 0.75%
Ropivacaine with normal saline 0.5ml added. The efficacy of
dexmedetomidine as an adjuvant in neuraxial analgesia   was studied in
50 patients in each group who underwent elective lower limb orthopedic
surgeries.
The patients in both the groups with respect to age, weight, ASA
Physical status did not show statistically significant difference.
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Duration of analgesia
The study had shown that  addition of  5µg of dexmedetomidine to
3ml of 0.75% Ropivacaine in group D prolongs the duration of analgesia
about 2 times of  the plain Ropivacaine group R. In group R duration of
analgesia was only 204.7 ± 20.61mins compared to group D which was
almost 2 times of group R 430.9 ± 33.08 mins. This result was concurrent
with the Gupta R et al (2011; 55:347-51) study where they concluded that
the  duration of analgesia was prolonged for about 478±20.9 minutes in
group D compared to group R which as only 241.67±21.67 minutes
duration.  This result was also correlated with the study Shukla et al
where they concluded that onset of anesthesia was faster with prolonged
duration of analgesia in the group (D) and also in the studies conducted
by Kallio et al11  (2011) & Vieira et al3 (2004).
TIME TO REGRESSION OF BLOCK TO S1
The time to regression of sensory blockade to S1 in group D was
423.3 ± 32.66 mins and in Group R was 189±23.44 mins which is nearly
three times for dexmedetomidine group when compared to plain
ropivacaine in our study and it is  statistically significant.This result was
correlated with following studies done by different authors.
1. Gupta R et al (2011):  had  found  out  that  the  mean  time  for  S2
segment regression was 468.3 ± 36.78 minutes in group D and
239.33  ± 16.8 minutes in group R.
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2. Kanazi GE et al: had observed that patients in dexmedetomidine
group D and Clonidine group C had early onset time of motor
block and a prolonged sensory and motor regression times than
plain bupivacaine group B which was statistically significant. The
mean time of S1 segment regression was 303 ±75 mins in group D,
272±38 mins in group C and 190±48 mins in group B.
3. Gupta R et al (2011): had observed that the mean time of sensory
level regression to S1 dermatome was 476 ± 23 mins in
dexmedetomidine group D and 187 ± 12 mins in fentanyl group F
(P<0.001).
4. Shukla et al: had found that faster onset and longer duration of
anesthesia in the dexmedetomidine group (D).
Duration of motor blockade
There is a significant prologation in duration of motor blockade in
group D with 271.46±33.40 mins when compared to group R i.e.
144.06±18.75 mins. These results correlate with following studies.
1. Kanazi et al: had observed that the motor block duration was 250
+/-76 mins in dexmedetomidine group D, 216±35 mins in
clonidine group C and 163 ± 47 mins in plain bupivacaine group B.
2. Gupta et al: evaluated the motor block duration was about 421 ±
21 min in dexmedetomidine group D and  about 149±18 min in
fentanyl group F (P<0.001). They found out that the spinal
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dexmedetomidine is associated with longer duration of motor and
sensory block.
3.  Al-Mustafa MM et al concluded that Dexmedetomidine has a
effect on the onset and regression of sensory and motor block in a
dose dependent manner, when used as an intrathecal adjuvant to
bupivacaine.
4 Eid HEA et al (22) concluded that the Intrathecal dexmedetomidine
in two different doses (10?g and 15?g) significantly prolong the
anesthetic and analgesic effects of intrathecal bupivacaine in a
dose-dependent manner.
5 Shukla et al (16) recorded onset time to reach peak sensory and
motor level, the regression time for sensory and motor block,
hemodynamic changes and side effects .They found that faster
onset of anesthesia with prolonged duration of analgesia in the
dexmedetomidine group.
Sedation score
The results of our study clearly indicate the sedation score between
the two groups was similar in the initial period after study drug
administration and they had profound sedation but arousable by gentle
tactile stimulation (i.e. four point verbal rating scale of 2). After 10mins,
the percentage of dexmedetomidine group patients who have scored
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higher sedation scores is more compared to group R. there was a
significant sedative effects for dexmedetomidine group of patients.
Hemodynamic stability
The heart rate, mean arterial pressure remained stable both during
introperative and postoperative period. Although a fall in heart rate and
blood pressure (both systolic and diastolic) was noted in both the groups,
it never decreased below the 20% of baseline values. But hypotension and
bradycardia were observed more in group D patients which is statistically
significant and it is correlated with the results of Gupta et al 2011, kanazi
et al.
SIDE EFFECTS
The incidence of bradycardia in Group R was 30% and in Group D
was 70% and there was statistically no significant difference in both
groups (p>0.05). The incidence of nausea and vomiting in Group R was
70%  and in Group D was 30% which was statistically not significant
(p>0.05). The incidence of shivering in Group R was 90% and in Group
D was 10% and there was statistically significant difference in both
groups (p<0.05).
The incidence of dry mouth in Group C was 50% and in Group D
was 50%. Statistically there was no significant difference in both groups
(p>0.05).These results had concurrence with the results of Eid HEA et al
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VAS SCORE
VAS score between group R and group D were found to be
significant during the whole period of observation (p<0.05) which
correlated with study done by Gupta et al which showed the maximum
visual analogue scale score for pain was less in group D (4.4±1.4) as
compared to group R (6.8±2.2).
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SUMMARY
This double blinded prospective randomized controlled study was
done to evaluate the duration of analgesia, sensory and motor blockade,
sedation and adverse effects of dexmedetomidine 5µg with 0.75%
isobaric Ropivacaine vs. plain 0.75% isobaric Ropivacaine given
intrathecally in patients who underwent lower limb orthopedic surgeries.
The following observations were made:
1. The addition of 5ug Dexmedetomidine to 0.75% Ropivacaine
significantly prolonged the duration of analgesia.
2. The addition of dexmedetomidine significantly prolonged the time
for demand analgesia.
3. The addition of dexmedetomidine intrathecally produced sedation
that was arousable for many hours compared to plain ropivacaine
group
4. The incidence of side effects such as hypotension and bradycardia
were more in patients who received dexmedetomidine but were
able to manage easily with inj.ephedrine and inj.atropine. But
shivering was greatly reduced in dexmedetomidine.
5. No episode of respiratory depression was noted in both the study
groups which are more common with opioids.
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CONCLUSION
To conclude  5ug of dexmedetomidine seems to be a better
adjuvant to intrathecal isobaric Ropivacaine (0.75%) in increasing the
duration of analgesia, prolonging the duration of sensory and motor
blockade with minimal side effects.
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INFORMATION TO PARTICIPANTS
Investigator :
Name of the Participant :
Title
Comparison of the Duration of  Analgesia, Duration of Sensory
And Motor Blockade and Incidence of Side Effects of Intrathecal 0.75%
Isobaric Ropivacaine with Combination of 0.75% Isobaric Ropivacaine
And Dexmedetomidine.
You are invited to take part in this research study. The information
in this document is meant to help you decide whether or not to take part.
Please feel free to ask if you have any queries or concerns.
You are being asked to participate in this study being conducted in
The Department of Anaesthesiology, Chengalpattu medical college
hospital, Chengalpattu.
What is the Purpose of the Research
For orthopaedic lower limb surgeries, intrathecal anesthesia is
administered with the drug 0.75% Ropivacaine with or without adjuvants.
This gives the pain relief for a reasonable period of time. In this we study
by adding Dexmedetomidine (selective alpha 2 agonists) to intrathecal
0.75% Ropivacaine and its effects on post operative analgesia.
The Study Design
All the patients in the study will be divided into two equal groups.
One group will receive intrathecal 0.75% Ropivacaine and another group
will receive intrathecal 0.75% Ropivacaine plus Dexmedetoimidine 5µg
Benefits
By  review  of  previous  study  post  operative  analgesia  after
intrathecal 0.75% Ropivacaine with Dexmedetomidine will be prolonged.
This drug also has sedative property which reduces the conception of
other sedative drugs.
Discomforts and risks
Hypotension and Bradycardia- common side effects of sedative ?2
agonists. Rarely nausea and vomiting also occur. Inj.Ondensetron will be
given for vomiting. Hypotension and Bradycardia will be treated with
Inj.Ephedrine, Inj.Atropine respectively.
And if you do not want to participate you will have alternative of
setting the standard treatment and your safety is our prime concern.
Time  :
Date :
Place :                                      Signature/Thumb impression of the Patient
Patient Name :
Signature of the Investigator : ____________________________
Name of the Investigator : _________________________
PROFORMA
Comparison of the Duration of  Analgesia, Duration of Sensory
And Motor Blockade and Incidence of Side Effects of Intrathecal 0.75%
Isobaric Ropivacaine with Combination of 0.75% Isobaric Ropivacaine
And Dexmedetomidine.
Name        Age/Sex        IP No Weight____kgs   Height ____ cms
Diagnosis  Procedure
H/O Previous surgery:
Co morbid illness:
Personal history:
H/O Allergy:
General examination:
Built & Nourishment
Pallor      / Cyanosis        / Clubbing           / Icterus       /  Pedal edema
PR         /min                     NIBP                mm/Hg           RR       / min
Airway examination: MPC                             Neck movements
Systemic examination:  CVS           RS               P/A                   CNS
INVESTIGATIONS
Hb%:                                   Platelet count:                      BT:                CT:
Blood sugar:                       Blood urea:                          Serum creatinine:
ECG:                                  Chest X ray:                         ECHO:
OPINION:
Assessment no & Date                                          ASA Physical status I/II
Pre operative preparation:
NPO:                                   Premedication:
PROCEDURE:
Preloading: Pre op: PR   / min, BP    mm/Hg, SpO2       %
Position:                 Study group:                         Spinal needle:
Time Events PR/min
NIBPm
m/ Hg
SpO2
%
Sensory
level
Motor
blockade VAS
Two
segment
regression
IV
Fluids
Side
effects
0 min
3 min
5 min
10 min
15 min
20 min
25 min
30 min
Time Events PR/min
NIBPm
m/ Hg
SpO2
%
Sensory
level
Motor
blockade VAS
Two
segment
regression
IV
Fluids
Side
effects
I hr
 2 hrs
3hrs
5 hrs
6hrs
7hrs
8hrs
9hrs
Rescue Analgesia:                                       Duration of sensory blockade
                                                                     Duration of motor block
 MASTER CHART
INTRATHECAL ISOBARIC 0.75%ROPIVACAINE
S.
No Name Age Sex Wt Procedure
ASA-
PS
Highest
sensory
level
obtained
Time to
attain
highest
sensory
level
Duration
of two
point
regression
Regression
of motor
blockade to
bromage 0
Duration
of
regression
to s1
segment
Duration of
analgesia
(in minutes)
1 Palani 48 M 60 # Both bone leg iln II T4 8 90 125 210 220
2 Saravanan 48 M 58 # Patella right tension band wiring II T6 10 100 136 210 215
3 Arumugam 52 M 50 # Femur neck orif I T6 7 90 135 200 210
4 Kumaresan 36 M 55 # Femur neck orif I T6 7 100 125 160 180
5 Sivaraj 60 M 67 # Patella right tension band wiring II T6 8 100 146 210 225
6 Indhu 45 F 65 #patella right tension band wiring I T8 8 90 155 205 225
7 Kalpana 31 F 48 #both bone leg iln I T4 11 100 145 200 220
8 Kanchana Devi 35 F 46 Raw area leg ssg I T8 13 90 156 220 220
9 Vijay 58 M 55 # Both bone leg iln II T6 9 100 125 160 180
10 Krishnaveni 27 F 55 # Patella right tension band wiring I T8 6 100 165 220 225
11 Kumar 60 m 67 # Femur neck orif ii t6 7 90 140 160 180
12 Kareema begum 29 f 54 # Both bone leg iln i t8 8 100 155 220 225
13 Madan 36 m 59 # Patella right tension band wiring i t4 9 90 115 160 180
14 Hariharan 53 m 56 #Both bone legiln i t6 11 100 115 160 180
15 Anandan 45 m 64 # Femur neck orif i t6 5 100 165 220 225
16 Perumalpitchay 58 m 59 # Patella right tension band wiring ii t8 8 90 115 160 180
17 Pugazhenthi 44 f 57 #Both bone leg iln i t6 7 100 165 210 225
18 Nagaraj 46 m 63 #Patella left tension band wiring i t4 7 90 115 160 180
19 Dillibabu 43 m 68 #Both bone leg iln i t6 8 100 175 220 225
20 Shehim begum 37 f 56 #Both bone leg iln i t6 10 100 125 160 180
21 Akkaiah 40 m 67 #Patella right tension band wiring i t6 12 90 155 205 225
22 Ramachandran 59 m 62 Raw area leg ssg ii t6 9 100 105 160 180
23 Velmurugan 34 m 58 # Femur neck orif i t4 7 90 155 220 225
24 Sivagami 21 f 45 # Both bone leg iln ii t6 6 100 105 160 180
25 Vasantha 22 f 50 Raw area leg ssg i
t4 7 100 115 160
180
26 Dhanush 28 m 60 # Both bone leg iln i
t6 7 90 155 200
225
27 Mumtaj 37 f 55 #Both bone leg iln i
t6 5 100 165 160
180
28 Rakkaiyee 40 f 67 #Patella right tension band wiring i
t6 6 90 145 180
225
29 Ram 59 m 62 Raw area leg ssg ii
t8 9 100 135 160
180
30 Mukunth 34 m 58 #Femur neck orif i
t6 8 100 125 160
180
31 Krishna 37 m 55 #Patella right tension band wiring i t8 9 90 155 180 225
32 Kumari 60 f 67 #Femur neck orif i t6 11 100 145 170 180
33 Katheeja 29 f 64 #Both bone leg iln i t6 5 90 165 215 225
34 Madhu 36 m 59 #Patella right tension band wiring i t6 6 100 135 170 185
35 Hari 53 m 56 #Both bone leg iln i t5 8 100 135 165 180
ORIF-OPEN REDUCTION AND INTERNAL FIXATION
SSG-SPLIT SKIN GRAFT
ILN-INTERLOCKING NAIL
36 Anandan 48 m 64 #Femur neck orif ii t6 8 90 175 200 225
37 Pitchay 58 m 59 #Patella right tension band wiring ii t6 8 100 135 180 180
38 Pushparani 44 f 57 #Both bone leg iln i t6 8 90 155 215 225
39 Raja 46 m 63 #Patella left tension band wiring i t5 9 100 135 175 180
40 Babu Raj 43 m 68 #Both bone leg iln i t8 9 100 156 210 220
41  Begum 37 f 56 #Both bone leg iln i t6 11 90 165 210 215
42 Muthamma 40 f 67 #Patella right tension band wiring i t4 9 100 144 200 210
43 Raman 59 m 62 Raw area leg ssg ii t8 9 90 135 170 180
44 Velu 34 m 58 #Femur neck orif i t6 8 100 155 210 225
45 Sivam 21 m 45 #Both bone leg iln ii t4 8 100 165 205 225
46 Vasu 22 f 50 Raw area leg ssg i
t6 8 90 165 210
220
47 Akash 28 m 60 #Both bone leg iln i
t8 8 100 165 220
220
48 Mangai 37 f 55 #Both bone leg iln i
t6 7 90 160 190
210
49 Rakky 40 f 67 #Patella right tension band wiring i
t4 6 100 145 180
215
50 ranjith reddy 59 m 62 raw area leg ssg ii t5 11 100 155 190 210
INTRATHECAL ISOBARIC 0.75%ROPIVACAINE PLUS DEXMEDETOMIDINE
S.
No
Name Age Sex Weight Procedure ASA-PS
Highest
sensory
level
obtained
Time to
attain
highest
sensory
level
Duration
of two
point
regression
Regression
of motor
blockade to
bromage 0
Duration
of
regression
to
s1segment
Duration of
Analgesia (in
minutes)
1 Gopal 55 m 55 #patella right tension
band wiring
ii t6 3 140 275 425 435
2 Samy 40 m 65 raw area leg ssg i t8 4 135 236 485 490
3 Subramaniam 35 m 59 #femur neck orif i t6 3 130 235 420 430
4 Seneka 35 f 53 #both bone leg iln i t6 5 140 225 380 390
5 Selvam 46 m 66 raw area leg ssg i t6 6 120 246 380
6 Sumathi 29 f 54 #both bone leg iln i t6 3 140 255 370 375
7 Varadarajan 32 m 58
#patella right tension
band wiring i
t6 4
135
245
380 390
8 Saranya 40 f 52 raw area leg ssg i t6 4 130 256 420 490
9 Sekar 45 m 68 #femur neck2orif ii t6 4 140 225 480 485
10 Panchatcharam 55 m 65 #both bone leg iln ii t6 4 120 265 420 430
11 Muuniyammal 45 f 64
#patella right tension
band wiring i
t6 5
140
240
430 435
12 Vijaya 50 f 55 raw area leg ssg ii t6 6 135 255 485 490
13 Arumugam 48 m 62 #femur neck orif i t4 5 130 265 420 425
14 Kumaravel 48 m 56 #both bone leg iln i t6 7 140 265 420 430
15 Adhilakshmi 53 f 48 raw area leg ssg i t6 8 120 265 485 490
16 Andavan 60 M 61 #both bone leg iln II T6 5 140 215 390 395
17 Chandra 45 F 54
#patella right tension
band wiring I
T6 9
135
265
410 430
18 Devaraj 40 M 46 tv&gj II T6 5 130 275 465 470
19 Pushparaj 49 M 67
#patella right tension
band wiring I
T6 5
140
285
390 395
20 Saravanan 48 M 54 raw area leg ssg I T6 8 130 265 425 430
21
Mohammed
Kadar 46 M 65 #femur neck orif I
T6 7
140
255
440 445
22 Meenal 45 F 68 #both bone leg iln II T6 7 135 305 405 410
23 Ramesh 30 M 61 raw area leg ssg I T6 8 130 285 415 430
24 Murugan 45 M 59 #both bone leg iln I T6 8 140 285 390 395
25 Thangavelu 57 M 65 #femur neck orif II T6 8 140 225 425 430
26 Katheresan 40 M 55 #both bone leg iln I T6 9 140 295 440 445
27 Lakshmi 53 F 48 raw area leg ssg I T6 9 135 275 405 410
28 Andal 61  F 61 #both bone leg iln II T6 11 130 265 425 430
29 Chandra 45 F 54
#patella right tension
band wiring I
T6 3
140
235
390 395
30 Devan 41 M 47 raw area leg ssg II T6 3 130 295 485 490
31 Maryammal 55 F 64
#patella right tension
band wirin I
T6 4
140
255
390 395
32 Alarmelmangai 50 F 55 raw area leg ssg II T6 4 135 245 425 430
33 Shanmugam 48 M 62 #femur neck orif I T6 4 130 265 440 445
34 Sannasi 55 M 56 #both bone leg iln I T6 4 140 235 405 410
35 Bahagyalakshmi 53 F 48 raw area leg ssg I T6 5 120 335 485 490
36 Anbu 60 M 61 #both bone leg iln II T6 5 140 375 390 395
37 Chitra 55 F 54
#patella right tension
band wiring I
T6 6
135
335
425 430
38 David 40 M 46 tv&gj II T6 6 130 315 440 445
39 Pushparaj 59 M 67
#patella right tension
band wiring I
T4 5
140
335
405 410
40 Saran 58 m 54 raw area leg ssg i t6 5 135 256 415 420
41 Kaleem 46 m 65 #femur neck ori2 i t6 6 130 265 465 470
42 Menaka 55 f 68 #both bone leg iln ii t4 3 140 244 390 395
43 Rameshwaran 30 m 61 raw area leg ssg i t8 5 120 265 425 430
44 Muniyaswamy 60 m 59 #both bone leg iln i t6 3 140 265 430 435
45 Velu 57 m 65 #femur neck orif ii t4 4 135 275 405 410
46 Nesamani 40 m 55 #both bone leg iln i t6 4 130 315 485 490
47 Lakshmiammal 60 f 48 raw area leg ssg i t8 3 140 305 390 395
48 Anjalakshi 51  f 61 #both bone leg iln ii t6 9 120 290 425 430
49 Cinthamani 55 f 54
#patella right tension
band wiring i
t4 11
140
315
440 445
50 Nanadakumar 60 m 47 raw area leg ssg ii t6 4 135 305 405 410
22RIF-OPEN REDUCTION AND INTERNAL FIXATION
2SG-SPLIT SKIN GRAFT ILN-INTERLOCKING NAIL
PULSE RATE –INTRATHECAL ISOBARIC 0.75%ROPIVACAINE
S
No
0
MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
25
MIN
30
MIN
60
MIN
120
MIN
180
MIN
240
MIN
300
MIN
360
MIN
420
MIN
480
MIN
540
MIN
1 87 76 78 74 74 77 73 86 90 96 120 105 96 96 98 106 106
2 86 82 87 89 83 95 103 113 111 93 95 90 91 102 94 100 102
3 89 73 86 90 96 120 99 97 109 107 99 88 90 109 109 100 110
4 84 73 89 89 98 98 97 108 99 108 108 96 98 95 98 97 95
5 83 77 84 96 90 87 93 90 97 89 93 95 103 83 95 105 96
6 83 73 83 95 105 96 96 83 89 82 87 89 83 95 103 87 99
7 73 73 83 95 105 96 96 83 120 105 96 96 98 120 105 98 98
8 78 78 78 88 93 90 97 89 93 93 92 90 105 96 96 98 120
9 86 86 85 96 90 97 93 96 89 99 92 90 83 95 105 96 96
10 74 74 84 84 89 94 93 90 97 89 92 90 60 93 90 97 89
11 79 79 80 84 84 97 73 74 73 89 92 90 87 89 83 95 103
12 87 87 89 89 89 105 96 96 98 120 88 98 99 99 99 98 98
13 87 87 89 90 90 103 93 82 82 91 105 96 96 98 120 94 94
14 93 93 90 97 89 93 93 90 93 90 97 89 93 93 90 97 89
15 84 84 89 94 93 90 84 89 94 99 99 87 90 99 89 98 98
16 89 89 89 89 95 105 96 96 98 120 91 90 84 92 91 94 94
17 90 90 90 90 95 103 83 95 105 95 103 83 95 63 63 109 109
18 89 89 89 89 89 83 95 103 87 89 83 95 103 53 59 98 98
19 63 63 75 88 95 103 83 95 105 95 103 83 95 103 83 95 105
20 95 95 103 83 95 105 96 95 95 103 83 95 89 83 95 103 87
S
No
0
MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
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MIN
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MIN
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MIN
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MIN
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MIN
240
MIN
300
MIN
360
MIN
420
MIN
480
MIN
540
MIN
21 89 89 83 95 103 87 99 89 89 83 95 103 95 103 83 95 105
22 67 67 89 95 103 83 95 105 59 95 103 83 95 103 83 95 105
23 95 95 103 89 83 95 103 87 90 89 83 95 103 83 95 105 96
24 89 89 83 95 103 83 95 105 92 95 103 83 83 95 103 87 99
25 95 95 103 89 83 95 103 87 91 89 83 95 95 103 83 95 105
26 79 79 80 84 84 97 73 74 73 89 92 90 87 89 83 95 103
27 87 87 89 89 89 105 96 96 98 120 88 98 99 99 99 98 98
28 87 87 89 90 90 103 93 82 82 91 105 96 96 98 120 94 94
29 93 93 90 97 89 93 93 90 93 90 97 89 93 93 90 97 89
30 84 84 89 94 93 90 84 89 94 99 99 87 90 99 89 98 98
31 74 74 84 84 89 94 93 90 97 89 92 90 60 93 90 97 89
32 79 79 80 84 84 97 73 74 73 89 92 90 87 89 83 95 103
33 87 87 87 89 90 105 96 96 98 120 88 98 99 99 99 98 98
34 87 93 93 90 97 103 93 82 82 91 105 96 96 98 120 94 94
35 93 84 84 89 94 93 93 90 93 90 97 89 93 93 90 97 89
36 84 74 74 84 84 90 84 89 94 99 99 87 90 99 89 98 98
37 89 79 79 80 84 105 96 96 98 120 91 90 84 92 91 94 94
38 90 87 87 89 90 103 83 95 105 95 103 83 95 63 63 109 109
39 89 93 93 90 97 83 95 103 87 89 83 95 103 53 59 98 98
40 63 84 84 89 94 103 83 95 105 95 103 83 95 103 83 95 105
41 95 74 74 84 84 105 96 95 95 103 83 95 89 83 95 103 87
42 89 79 79 80 84 87 99 89 89 83 95 103 95 103 83 95 105
S
No
0
MIN
3
MIN
5
MIN
10
MIN
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MIN
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MIN
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MIN
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MIN
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MIN
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MIN
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MIN
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MIN
540
MIN
43 67 87 87 89 90 83 95 105 59 95 103 83 95 103 83 95 105
44 87 87 89 90 97 95 103 87 90 89 83 95 103 83 95 105 96
45 93 93 90 89 94 83 95 105 92 95 103 83 83 95 103 87 99
46 84 84 89 84 84 95 103 87 91 89 83 95 95 103 83 95 105
47 74 74 84 84 84 97 73 74 73 89 92 90 87 89 83 95 103
48 79 79 80 89 89 105 96 96 98 120 88 98 99 99 99 98 98
49 87 87 89 90 90 103 93 82 82 91 105 96 96 98 120 94 94
50 93 93 90 97 89 93 93 90 93 90 97 89 93 93 90 97 89
PULSE RATE –INTRATHECAL ISOBARIC 0.75%ROPIVACAINE PLUS DEXMEDETOMIDINE
S No 0MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
25
MIN
30
MIN
60
MIN
120
MIN
180
MIN
240
MIN
300M
IN
360
MIN
420
MIN
480
MIN
540
MIN
1 88 88 56 57 58 59 59 58 58 58 56 56 57 58 59 59 58
2 91 91 60 60 61 62 62 59 59 59 61 60 60 61 62 62 59
3 88 88 67 66 65 68 65 69 65 65 64 67 66 65 68 65 69
4 78 78 57 57 55 59 57 58 58 58 56 57 57 55 59 57 58
5 86 86 63 63 62 61 66 63 64 64 64 63 63 62 61 66 63
6 88 88 58 47 49 54 55 49 55 55 58 58 47 49 54 55 49
7 83 83 65 67 67 64 64 63 66 66 66 65 67 67 64 64 63
8 88 88 56 57 58 59 59 58 58 58 56 56 57 58 59 59 58
9 91 91 60 60 61 62 62 59 59 59 61 60 60 61 62 62 59
10 88 88 56 57 58 59 59 58 58 65 64 67 66 65 68 65 69
11 78 78 60 60 61 62 62 59 59 58 56 57 57 55 59 57 58
12 86 86 67 66 65 68 65 69 65 58 56 56 57 58 59 59 58
13 88 88 88 57 55 59 57 58 58 59 61 60 60 61 62 62 59
14 83 64 91 63 62 61 66 63 64 65 64 67 66 65 68 65 69
15 88 88 88 47 49 54 55 49 55 58 56 57 57 55 59 57 58
16 91 91 78 67 67 64 64 63 66 64 64 63 63 62 61 66 63
17 88 88 86 57 58 59 59 58 58 55 58 58 47 49 54 55 49
18 78 78 88 60 61 62 62 59 59 66 66 65 67 67 64 64 63
19 86 86 83 66 65 68 65 69 65 58 56 56 57 58 59 59 58
20 88 88 88 57 55 59 57 58 58 59 61 60 60 61 62 62 59
S No 0MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
25
MIN
30
MIN
60
MIN
120
MIN
180
MIN
240
MIN
300M
IN
360
MIN
420
MIN
480
MIN
540
MIN
21 83 83 91 57 58 59 59 58 58 65 64 67 66 65 68 65 69
22 88 88 88 60 61 62 62 59 59 58 56 57 57 55 59 57 58
23 91 91 78 66 65 68 65 69 65 58 56 56 57 58 59 59 58
24 88 88 86 57 55 59 57 58 58 59 61 60 60 61 62 62 59
25 78 78 88 63 62 61 66 63 64 65 64 67 66 65 68 65 69
26 86 86 56 57 58 59 59 58 58 56 56 57 58 59 59 58 58
27 88 88 60 60 61 62 62 59 59 61 60 60 61 62 62 59 59
28 83 64 67 66 65 68 65 69 65 64 67 66 65 68 65 69 65
29 88 88 57 57 55 59 57 58 58 56 57 57 55 59 57 58 58
30 91 91 63 63 62 61 66 63 64 64 63 63 62 61 66 63 64
31 78 88 88 60 61 62 62 59 59 58 56 57 57 55 59 57 64
32 86 78 91 66 65 68 65 69 65 58 56 56 57 58 59 59 58
33 88 86 88 57 55 59 57 58 58 59 61 60 60 61 62 62 59
34 83 88 78 63 62 61 66 63 64 65 64 67 66 65 68 65 65
35 88 83 86 47 49 54 55 49 55 58 56 57 57 55 59 57 64
36 91 88 88 67 67 64 64 63 66 64 64 63 63 62 61 66 58
37 88 91 83 57 58 59 59 58 58 55 58 58 47 49 54 55 59
38 78 88 88 60 61 62 62 59 59 66 66 65 67 67 64 64 65
39 86 78 91 66 65 68 65 69 65 58 56 56 57 58 59 59 64
40 88 86 88 57 55 59 57 58 58 59 61 60 60 61 62 62 58
41 83 88 78 57 58 59 59 58 58 65 64 67 66 65 68 65 59
42 88 61 86 60 61 62 62 59 59 58 56 57 57 55 59 57 65
S No 0MIN
3
MIN
5
MIN
10
MIN
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MIN
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MIN
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MIN
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MIN
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IN
360
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420
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540
MIN
43 91 64 88 66 65 68 65 69 65 58 56 56 57 58 59 59 64
44 88 56 57 57 55 59 57 58 58 59 61 60 60 61 62 62 58
45 78 88 88 63 62 61 66 63 64 65 64 67 66 65 68 65 64
46 86 91 91 57 58 59 59 58 58 56 56 57 58 59 59 58 58
47 88 88 88 60 61 62 62 59 59 61 60 60 61 62 62 59 59
48 83 78 78 66 65 68 65 69 65 64 67 66 65 68 65 69 65
49 88 86 86 63 62 61 66 63 64 64 63 63 62 61 66 63 64
50 91 88 88 57 58 59 59 58 58 56 56 57 58 59 59 58 58
VISUAL ANALOGUE SCORE ––INTRATHECAL ISOBARIC 0.75%ROPIVACAINE
S.
 No
0
MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
25
MIN
30
MIN
60
MIN
120
MIN
180
MIN
240
MIN
300
MIN
360
MIN
420
MIN
480
MIN
540
MIN
1 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
2 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
3 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
4 0 0 0 4 3 3 4 4 4 4 4 4 4 4 4 4 4
5 0 0 0 4 3 3 4 4 4 4 4 4 4 4 4 4 4
6 0 0 0 4 3 3 4 4 4 4 4 4 4 4 4 4 4
7 0 0 0 4 3 3 4 4 4 4 4 4 4 4 4 4 4
8 0 0 0 3 3 3 4 4 4 4 4 4 4 4 4 4 4
9 0 0 0 2 2 3 3 3 3 3 3 3 3 3 4 4 4
10 0 0 0 2 2 3 3 3 3 3 3 3 3 3 4 4 4
11 0 0 0 2 2 2 3 3 3 3 3 3 3 3 4 4 4
12 0 0 0 4 3 4 4 4 4 4 4 4 4 4 4 4 4
13 0 0 0 4 3 4 4 4 4 4 4 4 4 4 4 4 4
14 0 0 0 4 3 4 4 4 4 4 4 4 4 4 4 4 4
15 0 0 0 2 2 3 3 3 3 3 3 3 3 3 4 4 4
16 0 0 0 1 2 3 2 2 2 2 2 2 2 2 4 4 4
17 0 0 0 1 2 3 2 2 2 2 2 2 2 2 4 4 4
18 0 0 0 1 2 2 2 2 2 2 2 2 2 2 4 4 4
19 0 0 0 1 2 2 2 2 2 2 2 2 2 2 4 4 4
20 0 0 0 1 2 3 2 2 2 2 2 2 2 2 4 4 4
21 0 0 0 1 2 3 2 2 2 3 3 3 3 3 4 4 4
22 0 0 0 3 3 3 4 4 4 4 4 4 4 4 4 4 4
23 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
24 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
25 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
26 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
27 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
28 0 0 0 4 3 3 4 4 4 4 4 4 4 4 4 4 4
29 0 0 0 4 3 3 4 4 4 4 4 4 4 4 4 4 4
30 0 0 0 4 3 3 4 4 4 4 4 4 4 4 4 4 4
31 0 0 0 2 2 2 3 3 3 3 3 3 3 3 4 4 4
32 0 0 0 4 3 4 4 4 4 4 4 4 4 4 4 4 4
33 0 0 0 4 3 4 4 4 4 4 4 4 4 4 4 4 4
34 0 0 0 4 3 4 4 4 4 4 4 4 4 4 4 4 4
35 0 0 0 2 2 3 3 3 3 3 3 3 3 3 4 4 4
36 0 0 0 1 2 3 2 2 2 2 2 2 2 2 4 4 4
37 0 0 0 1 2 3 2 2 2 2 2 2 2 2 4 4 4
38 0 0 0 1 2 2 2 2 2 2 2 2 2 2 4 4 4
39 0 0 0 1 2 2 2 2 2 2 2 2 2 2 4 4 4
40 0 0 0 1 2 3 2 2 2 2 2 2 2 2 4 4 4
41 0 0 0 1 2 3 2 2 2 3 3 3 3 3 4 4 4
42 0 0 0 3 3 3 4 4 4 4 4 4 4 4 4 4 4
43 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
44 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
45 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
46 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
47 0 0 0 2 3 3 3 3 3 3 3 3 3 3 4 4 4
48 0 0 0 4 3 3 4 4 4 4 4 4 4 4 4 4 4
49 0 0 0 4 3 3 4 4 4 4 4 4 4 4 4 4 4
50 0 0 0 4 3 3 4 4 4 4 4 4 4 4 4 4 4
VISUAL ANALOGUE SCORE–GROUP D
S
No
0
MI
N
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
25
MIN
30
MIN
60
MIN
120
MIN
180
MIN
240
MIN
300
MIN
36O
MIN
420
MIN
480
MIN
540
MIN
1 0 0 0 0 0 0 0 1 2 3 3 3 3 3 3 4 4
2 0 0 0 0 0 0 0 1 1 3 2 3 3 3 4 4 4
3 0 0 0 0 0 0 0 1 1 3 3 3 3 3 2 4 4
4 0 0 0 0 0 0 0 1 1 3 3 3 3 3 3 4 4
5 0 0 0 0 0 0 0 1 1 3 3 3 3 3 3 4 4
6 0 0 0 0 0 0 0 1 1 2 3 3 3 3 4 4 4
7 0 0 0 0 0 0 0 1 1 2 2 2 3 3 3 3 4
8 0 0 0 0 0 0 0 1 1 3 3 3 3 3 2 3 2
9 0 0 0 0 0 0 0 1 3 3 3 3 3 2 3 2 4
10 0 0 0 0 0 0 0 1 1 2 2 2 3 2 2 2 4
11 0 0 0 0 0 0 0 1 1 2 2 2 3 3 3 4 4
12 0 0 0 0 0 0 0 1 1 2 2 2 3 3 2 3 4
13 0 0 0 0 0 0 0 1 1 3 3 3 2 3 2 2 4
14 0 0 0 0 0 0 0 1 1 3 3 3 2 2 3 3 4
15 0 0 0 0 0 0 0 1 1 2 3 3 3 3 2 3 4
16 0 0 0 0 0 0 0 1 1 2 3 3 2 3 2 3 2
17 0 0 0 0 0 0 0 1 2 3 3 3 2 2 2 2 2
18 0 0 0 0 0 0 0 1 2 3 3 3 3 3 3 3 3
19 0 0 0 0 0 0 0 1 3 3 3 3 2 3 2 3 2
20 0 0 0 0 0 0 0 1 3 3 3 3 2 2 2 2 2
21 0 0 0 0 0 0 0 1 2 3 3 3 3 3 3 3 3
22 0 0 0 0 0 0 0 1 2 3 2 2 2 3 2 3 2
23 0 0 0 0 0 0 0 1 2 3 2 2 2 2 2 2 2
24 0 0 0 0 0 0 0 1 3 3 3 2 3 3 3 3 3
25 0 0 0 0 0 0 0 1 2 3 2 2 3 3 2 3 2
26 0 0 0 0 0 0 0 1 1 2 3 3 2 3 2 3 2
27 0 0 0 0 0 0 0 1 2 3 3 3 2 2 2 2 2
28 0 0 0 0 0 0 0 1 2 3 3 3 3 3 3 3 3
29 0 0 0 0 0 0 0 1 3 3 3 3 2 3 2 3 2
30 0 0 0 0 0 0 0 1 3 3 3 3 2 2 2 2 2
31 0 0 0 0 0 0 0 1 1 2 2 2 3 3 3 4 4
32 0 0 0 0 0 0 0 1 1 2 2 2 3 3 2 3 4
33 0 0 0 0 0 0 0 1 1 3 3 3 2 3 2 2 4
34 0 0 0 0 0 0 0 1 1 3 3 3 2 2 3 3 4
35 0 0 0 0 0 0 0 1 1 2 3 3 3 3 2 3 4
36 0 0 0 0 0 0 0 1 1 2 3 3 2 3 2 3 2
37 0 0 0 0 0 0 0 1 2 3 3 3 2 2 2 2 2
38 0 0 0 0 0 0 0 1 2 3 3 3 3 3 3 3 3
39 0 0 0 0 0 0 0 1 3 3 3 3 2 3 2 3 2
40 0 0 0 0 0 0 0 1 3 3 3 3 2 2 2 2 2
41 0 0 0 0 0 0 0 1 2 3 3 3 3 3 3 3 3
42 0 0 0 0 0 0 0 1 2 3 2 2 2 3 2 3 2
43 0 0 0 0 0 0 0 1 2 3 2 2 2 2 2 2 2
44 0 0 0 0 0 0 0 1 3 3 3 2 3 3 3 3 3
45 0 0 0 0 0 0 0 1 2 3 2 2 3 3 2 3 2
46 0 0 0 0 0 0 0 1 1 2 3 3 2 3 2 3 2
47 0 0 0 0 0 0 0 1 2 3 3 3 2 2 2 2 2
48 0 0 0 0 0 0 0 1 2 3 3 3 3 3 3 3 3
49 0 0 0 0 0 0 0 1 3 3 3 3 2 3 2 3 2
50 0 0 0 0 0 0 0 1 3 3 3 3 2 2 2 2 2
SATURATION –GROUP R
S
No
0
MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
25
MIN
30
MIN
60
MIN
120
MIN
180
MIN
240
MIN
300
MIN
36O
MIN
420
MIN
480
MIN
540
MIN
1 98% 99% 99% 98% 99% 99% 98% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
2 98% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
3 99% 99% 98% 98% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
4 98% 98% 97% 98% 98% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
5 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
6 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
7 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
8 100% 100% 100% 100% 100% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
9 100% 100% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
10 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
11 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
12 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
13 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
14 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
15 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
16 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
17 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
18 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
19 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
20 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
21 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
22 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
23 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
24 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
25 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
26 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
27 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
28 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
29 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
30 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99%
31 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99%
32 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99%
33 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99%
34 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99%
35 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99%
36 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99%
37 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99%
38 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99%
39 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99%
40 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
41 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
42 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
43 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
44 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
45 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
46 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
47 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
48 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
49 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
50 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
SATURATION –GROUP D
S
No
420
MIN
0
MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
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MIN
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MIN
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MIN
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MIN
180
MIN
240
MIN
300
MIN
36O
MIN
480
MIN
540
MIN
1 100% 98% 99% 99% 98% 99% 99% 98% 100% 100% 100% 100% 100% 100% 100% 100% 100%
2 100% 98% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
3 100% 99% 99% 98% 98% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
4 100% 98% 98% 97% 98% 98% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
5 100% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
6 98% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 98%
7 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100% 99% 99% 99%
8 99% 100% 100% 100% 100% 100% 99% 99% 100% 100% 100% 100% 100% 100% 99% 99% 99%
9 99% 100% 100% 99% 99% 99% 99% 99% 100% 99% 98% 99% 98% 99% 99% 99% 99%
10 98% 99% 98% 99% 98% 99% 99% 99% 100% 99% 99% 99% 99% 99% 99% 99% 98%
11 99% 99% 99% 99% 99% 99% 99% 100% 99% 99% 99% 99% 99% 99% 99% 99% 99%
12 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
13 99% 99% 99% 99% 99% 99% 100% 99% 99% 99% 98% 99% 98% 99% 99% 99% 99%
14 98% 99% 98% 99% 98% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 98%
15 99% 99% 99% 99% 99% 99% 100% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
16 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
17 99% 99% 99% 99% 99% 99% 100% 99% 99% 99% 98% 99% 98% 99% 99% 99% 99%
18 98% 99% 98% 99% 98% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 98%
19 99% 99% 99% 99% 99% 99% 100% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
20 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
21 99% 99% 99% 99% 99% 99% 100% 99% 99% 99% 98% 99% 98% 99% 99% 99% 99%
22 98% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 98%
23 99% 99% 99% 99% 99% 99% 100% 99% 100% 99% 99% 99% 99% 99% 99% 99% 99%
24 99% 99% 99% 99% 99% 99% 99% 99% 100% 99% 99% 99% 99% 99% 99% 99% 99%
25 99% 99% 99% 99% 99% 99% 100% 99% 100% 99% 98% 99% 98% 99% 99% 99% 99%
26 98% 99% 99% 99% 99% 99% 99% 99% 99% 98% 99% 98% 99% 98% 99% 99% 98%
27 99% 99% 99% 99% 99% 99% 100% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
28 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
29 99% 99% 99% 99% 99% 99% 100% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%
30 100% 99% 99% 99% 99% 99% 99% 99% 99% 98% 99% 98% 99% 98% 99% 100% 100%
31 99% 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99%
32 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99%
33 99% 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99%
34 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99%
35 99% 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99%
36 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99%
37 99% 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99%
38 99% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99%
39 99% 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 99% 99%
40 100% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
41 100% 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
42 100% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
43 100% 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
44 100% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
45 100% 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
46 100% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
47 100% 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
48 100% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
49 100% 99% 99% 99% 99% 99% 100% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
50 100% 99% 99% 99% 99% 99% 99% 99% 100% 100% 100% 100% 100% 100% 100% 100% 100%
FOUR POINT VERBAL RATING SCALE –GROUP R
S
No
0
MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
25
MIN
30
MIN
60
MIN
120
MIN
180
MIN
240
MIN
300
MIN
36O
MIN
420
MIN
480
MIN
540
MIN
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
12 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
13 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
14 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
15 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
16 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
17 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
18 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
19 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
20 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
21 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
22 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
23 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
24 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
25 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
26 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
27 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
28 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
29 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
30 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
31 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
32 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
33 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
34 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
35 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
36 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
37 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
38 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
39 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
40 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
41 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
42 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
43 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
44 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
45 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
46 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
47 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
48 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
49 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
50 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
FOUR POINT VERBAL RATING SCALE – GROUP D
S
No
0
MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
25
MIN
30
MIN
60
MIN
120
MIN
180
MIN
240
MIN
300
MIN
36O
MIN
420
MIN
480
MIN
540
MIN
1 1 1 1 2 2 2 3 3 3 2 2 2 1 1 1 1 1
2 1 1 1 2 2 2 3 3 3 2 2 2 1 1 1 1 1
3 1 1 1 2 2 2 3 3 3 3 3 3 1 1 1 1 1
4 1 1 1 2 2 3 2 2 3 3 2 2 1 1 1 1 1
5 1 1 1 3 3 3 3 3 3 3 2 2 1 1 1 1 1
6 1 1 1 3 3 3 3 3 3 2 2 2 1 1 1 1 1
7 1 1 1 3 3 2 3 2 2 2 3 1 1 1 1 1 1
8 1 1 1 2 2 2 3 3 3 3 3 1 1 1 1 1 1
9 1 1 1 2 2 2 3 3 3 3 3 2 2 2 1 1 1
10 1 1 1 2 2 3 3 3 3 3 3 2 2 2 1 1 1
11 1 1 1 2 2 3 3 3 3 3 3 2 2 2 1 1 1
12 1 1 1 2 2 3 3 3 3 3 3 2 2 2 1 1 1
13 1 1 1 2 2 2 3 3 3 3 3 2 2 2 1 1 1
14 1 1 1 2 2 2 3 3 3 2 2 2 2 2 1 1 1
15 1 1 1 3 3 2 3 2 2 2 2 1 1 1 1 1 1
16 1 1 1 2 3 3 3 3 2 2 2 1 1 1 1 1 1
17 1 1 1 2 3 3 3 3 2 2 2 1 1 1 1 1 1
18 1 1 1 2 3 3 3 3 3 3 3 2 2 2 1 1 1
19 1 1 1 2 3 2 3 3 3 3 3 2 2 2 1 1 1
20 1 1 1 2 3 2 3 3 3 3 3 2 2 2 1 1 1
21 1 1 1 2 3 3 3 3 3 3 3 2 2 2 1 1 1
22 1 1 1 2 3 3 3 3 3 3 3 2 2 2 1 1 1
23 1 1 1 2 3 3 3 3 3 2 2 1 1 1 1 1 1
24 1 1 1 2 3 3 3 3 3 2 2 2 2 2 1 1 1
25 1 1 1 2 3 3 3 3 3 3 3 2 2 2 1 1 1
26 1 1 1 2 3 3 3 3 3 3 3 2 2 2 1 1 1
27 1 1 1 3 3 3 2 2 2 2 2 1 1 1 1 1 1
28 1 1 1 3 3 3 3 3 3 3 3 2 2 2 1 1 1
29 1 1 1 3 3 3 3 3 3 3 3 2 2 2 1 1 1
30 1 1 1 2 2 3 3 3 3 3 3 2 2 2 1 1 1
31 1 1 1 2 2 3 3 3 3 3 3 2 2 2 1 1 1
32 1 1 1 2 2 3 2 2 2 2 2 2 2 2 1 1 1
33 1 1 1 2 3 3 2 2 2 2 2 2 2 2 1 1 1
34 1 1 1 2 3 3 3 3 3 3 3 2 2 2 1 1 1
35 1 1 1 2 3 3 2 2 2 2 2 1 1 1 1 1 1
36 1 1 1 2 3 3 2 2 2 2 2 1 1 1 1 1 1
37 1 1 1 3 3 3 2 2 2 2 2 1 1 1 1 1 1
38 1 1 1 3 2 3 3 3 2 2 2 2 2 2 1 1 1
39 1 1 1 3 2 3 3 3 2 2 2 2 2 2 1 1 1
40 1 1 1 3 3 3 3 3 2 2 2 2 2 2 1 1 1
41 1 1 1 3 3 3 3 3 2 2 2 2 2 2 1 1 1
42 1 1 1 2 3 3 3 3 3 3 3 2 2 2 1 1 1
43 1 1 1 2 3 3 3 3 3 2 2 1 1 1 1 1 1
44 1 1 1 2 3 3 3 3 3 2 2 2 2 2 1 1 1
45 1 1 1 2 3 3 3 3 3 3 3 2 2 2 1 1 1
46 1 1 1 2 3 3 3 3 3 3 3 2 2 2 1 1 1
47 1 1 1 2 3 3 2 2 2 2 2 1 1 1 1 1 1
48 1 1 1 2 3 3 3 3 3 3 3 2 2 2 1 1 1
49 1 1 1 2 2 3 3 3 3 3 3 2 2 2 1 1 1
50 1 1 1 2 2 3 3 3 3 2 2 2 2 2 1 1 1
MEAN ARTERIAL PRESURE-GROUP R
S
No
0
MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
25
MIN
30
MIN
60
MIN
120
MIN
180
MIN
240
MIN
300
MIN
360
MIN
420
MIN
480
MIN
540
MIN
1 110 96 96 87 88 99 99 96 96 87 96 96 101 102 112 121 111
2 119 90 90 80 91 102 102 90 90 80 90 90 108 109 119 126 128
3 111 96 89 99 88 99 99 96 89 99 96 89 111 102 112 121 111
4 117 90 99 99 78 99 96 90 99 99 90 99 105 109 119 126 128
5 116 96 99 99 86 99 98 96 99 99 96 99 106 102 112 121 111
6 100 90 89 99 88 99 94 90 89 99 90 89 107 102 112 121 111
7 109 86 99 99 83 99 92 86 99 99 86 99 108 119 119 126 128
8 108 96 96 87 88 99 99 96 96 87 96 96 101 102 112 121 111
9 109 90 90 80 91 102 102 90 90 80 90 90 108 109 119 126 128
10 120 96 89 99 88 99 99 96 89 99 96 89 105 122 112 121 111
11 108 90 99 99 78 99 96 90 99 99 90 99 111 122 112 121 111
12 126 96 99 99 86 99 98 96 99 99 96 99 128 129 119 126 128
13 121 90 89 99 88 99 94 90 89 99 90 89 111 122 112 121 111
14 126 86 99 99 83 99 92 86 99 99 86 99 128 129 119 126 128
15 111 96 96 87 88 99 99 96 96 87 88 99 111 122 112 121 111
16 126 90 90 80 91 102 102 90 90 80 91 102 101 122 112 121 111
17 121 96 89 99 88 99 99 96 89 99 88 99 108 129 119 126 128
18 107 90 99 99 78 99 96 90 99 99 88 99 111 122 112 121 111
19 105 96 99 99 86 99 98 96 99 99 86 99 108 129 119 126 128
20 106 90 89 99 88 99 94 90 89 99 88 99 106 122 112 121 111
S
No
0
MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
25
MIN
30
MIN
60
MIN
120
MIN
180
MIN
240
MIN
300
MIN
360
MIN
420
MIN
480
MIN
540
MIN
21 111 86 99 99 83 99 92 86 99 99 83 99 106 122 112 121 111
22 106 96 96 87 88 99 99 96 96 87 88 99 101 102 101 102 128
23 121 90 90 80 91 102 102 90 90 80 91 102 108 109 108 109 111
24 106 96 89 99 88 99 99 96 89 99 88 99 111 102 111 102 128
25 121 90 99 99 78 99 96 90 99 99 78 99 105 109 105 109 111
26 106 96 99 99 86 99 98 96 99 99 86 99 111 122 112 121 111
27 101 90 89 99 88 99 94 90 89 99 88 99 128 129 119 126 128
28 116 86 99 99 83 99 92 86 99 99 83 99 111 122 112 121 111
29 111 96 96 87 88 99 99 96 96 87 88 99 108 129 119 126 128
30 106 90 90 80 91 102 102 90 90 80 91 102 101 122 112 121 111
31 108 90 99 99 78 99 96 90 99 99 90 99 111 122 112 121 102
32 126 96 99 99 86 99 98 96 99 99 96 99 128 129 119 126 109
33 121 90 89 99 88 99 94 90 89 99 90 89 111 122 112 121 102
34 126 86 99 99 83 99 92 86 99 99 86 99 128 129 119 126 109
35 111 96 96 87 88 99 99 96 96 87 88 99 111 122 112 121 121
36 126 90 90 80 91 102 102 90 90 80 91 102 101 122 112 121 126
37 121 96 89 99 88 99 99 96 89 99 88 99 108 129 119 126 102
38 122 90 99 99 78 99 96 90 99 99 88 99 111 122 112 121 109
39 129 96 99 99 86 99 98 96 99 99 86 99 108 129 119 126 102
40 122 90 89 99 88 99 94 90 89 99 88 99 106 122 112 121 109
41 122 86 99 99 83 99 92 86 99 99 83 99 106 122 112 121 121
42 102 96 96 87 88 99 99 96 96 87 88 99 101 102 101 102 126
S
No
0
MIN
3
MIN
5
MIN
10
MIN
15
MIN
20
MIN
25
MIN
30
MIN
60
MIN
120
MIN
180
MIN
240
MIN
300
MIN
360
MIN
420
MIN
480
MIN
540
MIN
43 109 90 90 80 91 102 102 90 90 80 91 102 108 109 108 109 102
44 122 96 83 99 92 86 99 99 83 99 88 99 111 102 111 102 109
45 129 90 88 99 99 96 96 87 88 99 78 99 105 109 105 109 102
46 122 96 91 102 102 90 90 80 91 102 86 99 111 122 112 121 109
47 122 90 83 99 92 86 99 99 83 99 88 99 128 129 119 126 121
48 102 86 88 99 99 96 96 87 88 99 83 99 111 122 112 121 126
49 109 96 96 87 88 99 99 96 96 87 88 99 108 129 119 126 102
50 122 90 90 80 91 102 102 90 90 80 91 102 101 122 112 121 109
MEAN ARTERIAL PRESURE-GROUP D
S
No
0
MIN
3
MIN
5
MIN
10
MIN 15 MIN
20
MIN
25
MIN 30 MIN
60
MIN
120
MIN
180
MIN 240 MIN
300
MIN
360
MIN
420
MIN 480 MIN
540
MIN
1 110 96 96 87 88 89 89 88 90 100 104 98 97 88 89 89 88
2 119 90 90 80 91 75 72 79 80 89 81 90 90 91 92 92 89
3 111 96 89 99 88 60 65 69 88 90 100 104 88 90 68 65 69
4 117 90 99 99 78 61 57 58 79 80 89 81 79 80 59 57 58
5 116 96 99 99 86 67 88 90 100 90 100 104 88 90 61 66 63
6 100 90 89 99 88 60 79 80 89 80 89 81 79 80 54 55 49
7 109 86 99 99 83 68 88 90 100 88 90 100 104 88 90 100 104
8 108 96 96 87 88 67 79 80 89 79 80 89 81 79 80 89 81
9 109 90 90 80 91 60 88 90 100 88 90 100 104 88 90 100 104
10 120 96 89 99 88 59 79 80 89 79 80 89 81 79 80 89 81
11 108 90 99 99 78 62 88 90 100 88 90 100 104 88 90 100 104
12 126 96 99 99 86 68 65 69 79 79 80 89 81 79 80 89 81
13 121 90 89 99 88 59 67 75 78 88 90 100 104 88 90 100 104
14 126 86 99 99 83 61 66 63 64 65 64 67 86 95 98 95 109
15 111 96 96 87 88 68 68 65 69 79 79 80 68 88 95 97 101
16 126 90 90 80 91 67 59 67 75 78 88 90 67 96 98 95 102
17 121 96 89 99 88 68 68 65 69 79 79 80 68 95 98 95 99
18 107 90 99 99 78 67 59 67 75 78 88 90 86 95 98 95 109
19 105 96 99 99 86 68 68 65 69 79 79 80 68 88 95 97 101
20 106 90 89 99 88 67 59 67 75 78 88 90 67 96 98 95 102
21 111 86 99 99 83 61 59 58 58 65 64 67 68 95 98 95 49
22 106 96 96 87 88 65 62 59 59 58 56 57 86 95 98 95 109
23 121 90 90 80 91 60 65 69 65 58 56 56 68 88 95 97 101
24 106 96 89 99 88 61 57 58 58 59 61 60 67 96 98 95 102
25 121 90 99 99 78 65 66 63 64 65 64 67 76 85 78 85 89
26 106 96 99 99 86 60 59 58 58 86 95 98 95 109 86 95 98
S
No
0
MIN
3
MIN
5
MIN
10
MIN 15 MIN
20
MIN
25
MIN 30 MIN
60
MIN
120
MIN
180
MIN 240 MIN
300
MIN
360
MIN
420
MIN 480 MIN
540
MIN
27 101 90 89 99 88 61 62 59 59 68 88 95 97 101 78 88 95
28 116 86 99 99 83 65 65 69 65 67 96 98 95 102 87 96 98
29 111 96 96 87 88 60 57 58 58 68 95 98 95 49 68 95 98
30 106 90 90 80 91 61 66 63 64 86 95 98 95 109 86 95 98
31 108 90 99 99 78 62 88 90 100 88 90 100 104 88 90 100 104
32 126 96 99 99 86 68 65 69 79 79 80 89 81 79 80 89 81
33 121 90 89 99 88 59 67 75 78 88 90 100 104 88 90 100 104
34 126 86 99 99 83 61 66 63 64 65 64 67 86 95 98 95 109
35 111 96 96 87 88 68 68 65 69 79 79 80 68 88 95 97 101
36 126 90 90 80 91 67 59 67 75 78 88 90 67 96 98 95 102
37 121 96 89 99 88 68 68 65 69 79 79 80 68 95 98 95 99
38 122 90 99 99 78 67 59 67 75 78 88 90 86 95 98 95 109
39 129 96 99 99 86 68 68 65 69 79 79 80 68 88 95 97 101
40 122 90 89 99 88 67 59 67 75 78 88 90 67 96 98 95 102
41 122 86 99 99 83 61 59 58 58 65 64 67 68 95 98 95 49
42 102 96 96 87 88 65 62 59 59 58 56 57 86 95 98 95 109
43 109 90 90 80 91 60 65 69 65 58 56 56 68 88 95 97 101
44 122 96 83 99 92 61 57 58 58 59 61 60 67 96 98 95 102
45 129 90 88 99 99 65 66 63 64 65 64 67 76 85 78 85 89
46 122 96 91 102 102 60 59 58 58 86 95 98 95 109 86 95 98
47 122 90 83 99 92 61 62 59 59 68 88 95 97 101 78 88 95
48 102 86 88 99 99 65 65 69 65 67 96 98 95 102 87 96 98
49 109 96 96 87 88 60 57 58 58 68 95 98 95 49 68 95 98
50 122 90 90 80 91 61 66 63 64 86 95 98 95 109 86 95 98
SIDE EFFECTS – GROUP R
S.No Hypotension Bradycardia Nausea Voiting Shivering Dry mouth
1 NO YES NO NO NO NO
2 NO NO NO NO NO NO
3 NO NO NO NO YES NO
4 NO NO NO YES YES NO
5 NO NO NO YES YES NO
6 YES NO NO YES YES NO
7 NO NO NO YES YES NO
8 NO NO NO YES YES NO
9 NO NO NO YES NO NO
10 YES NO NO YES YES NO
11 NO NO NO NO YES NO
12 NO NO NO NO YES NO
13 NO NO NO NO YES NO
14 NO NO NO NO YES NO
15 NO NO NO NO YES NO
16 NO NO NO NO YES NO
17 NO NO NO NO NO NO
18 NO NO NO NO NO NO
19 NO NO NO NO NO NO
20 NO NO NO NO NO NO
21 NO NO NO NO NO NO
22 NO NO NO NO NO NO
23 NO NO NO NO NO NO
24 NO NO NO NO NO NO
25 NO NO NO NO NO NO
26 NO NO NO NO NO NO
27 NO NO NO NO NO NO
28 NO NO YES NO NO NO
29 YES NO YES NO NO NO
30 YES NO YES NO NO YES
31 NO NO NO NO YES NO
32 NO NO NO NO YES NO
33 NO NO NO NO YES NO
34 NO NO NO NO YES NO
35 NO NO NO NO YES NO
36 NO NO NO NO YES NO
37 NO NO NO NO NO NO
38 NO NO NO NO NO NO
39 NO NO NO NO NO YES
40 NO NO NO NO NO NO
41 NO NO NO NO NO NO
42 NO NO NO NO NO NO
43 NO NO NO NO NO NO
44 NO NO NO NO NO NO
45 NO NO NO NO NO NO
46 NO NO NO NO NO NO
47 NO YES YES NO NO NO
48 NO NO YES NO NO NO
49 YES NO YES NO NO NO
50 YES YES YES NO NO NO
SIDE EFFECTS – GROUP D
S. No Hypotension Bradycardia Nausea Vomiting Shivering Dry mouth
1 NO NO NO NO NO NO
2 NO YES NO NO NO NO
3 NO NO YES YES NO NO
4 NO NO NO NO NO NO
5 NO NO NO NO NO NO
6 NO NO NO NO NO NO
7 NO NO NO NO NO NO
8 NO NO NO NO NO NO
9 NO NO NO NO NO NO
10 NO NO NO NO NO NO
11 NO NO NO NO NO NO
12 NO NO NO NO NO NO
13 NO NO NO NO NO NO
14 NO NO NO NO NO NO
15 NO NO NO NO NO NO
16 NO YES YES YES NO NO
17 NO NO NO NO NO NO
18 NO YES NO NO NO YES
19 NO YES NO NO NO YES
20 YES NO NO NO NO YES
21 NO NO NO NO NO NO
22 NO NO NO NO NO NO
23 YES NO NO NO NO NO
24 NO NO NO NO NO NO
25 NO NO NO NO NO NO
26 YES NO NO NO NO NO
27 NO NO NO NO NO NO
28 NO NO NO NO NO NO
29 YES NO NO NO NO NO
30 NO NO NO NO NO NO
31 NO NO NO NO NO NO
32 NO NO NO NO NO NO
33 NO NO NO NO NO NO
34 NO NO NO NO NO NO
35 NO NO NO NO NO NO
36 NO YES YES YES NO NO
37 YES NO NO NO NO NO
38 NO YES NO NO NO NO
39 NO YES NO NO NO NO
40 YES NO NO NO NO NO
41 NO NO NO NO NO NO
42 NO NO NO NO NO NO
43 YES NO NO NO NO NO
44 NO NO NO NO NO NO
45 NO NO NO NO NO NO
46 YES NO NO NO YES NO
47 NO NO NO NO NO NO
48 NO NO NO NO NO NO
49 YES NO NO NO YES NO
50 NO NO NO NO NO NO
